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Abstract 
Expression of the tryptophan (TRP)-catabolizing enzyme indoleamine 2,3-
dioxygenase (IDO) in various types of dendritic cells (DCs) has been associated with 
suppression of T cell mediated immune responses, including suppression of 
immunological cancer control. In this project, we studied whether the T cell 
stimulatory capacity of murine hematopoietic stem cell-derived DCs (HSC-derived 
DCs) is affected by IDO activity. 
We show that activation of HSC-derived DCs from C57BL/6 mice with 
lipopolysaccharide (LPS) and interferon-gamma (IFN-γ) up-regulated CD80, CD86, 
major histocompatibility complexes class II (MHC class II), and CD40 expression, as 
well as T helper cell 1 (Th1) response cytokine secretion, compatible with an 
activated phenotype. While showing IDO activity in human DCs, activation up-
regulates IDO messenger ribonucleic acid (mRNA), but does not induce IDO 
enzymatic activity in murine DCs. To exclude insufficient gene transcription that 
would lead to attenuated IDO protein expression and hence to enzymatic activity 
below detection limit, HSC-derived DCs were transfected with an IDO-encoding 
vector by electroporation technique. Despite significant and stable over-expression of 
both, IDO mRNA and protein, IDO activity was still undetectable in these cells. To 
study the stimulatory capacity of these DCs co-cultures with syngeneic T cell receptor 
(TCR) transgenic ovalbumin (OVA) specific CD4 (OT-II) or CD8 (OT-I) T cells were 
performed. As expected, we found vigorous T cell responses that were proportional 
to the number of OVA-peptide pulsed activated DCs. LPS and IFN-γ stimulation of 
HSC-derived DCs also activated inducible nitric oxide synthase (iNOS) and hence 
the production of NO which has been reported to be a powerful inhibitor of IDO 
activity. We found levels of NO in our cultures comparable to those found in other 
studies that inhibited IDO activity. Interestingly, iNOS activity was undetectable in 
various murine (Raw264.7 and J558) and human (Phoenix and HeLa) cell lines that 
exhibited effective IDO activity after transfection with the equivalent IDO-encoding 
vector. 
In summary, we suggest that murine HSC-derived DCs maintain IDO in an 
enzymatically inactive form. IDO expression in murine HSC-derived DCs, when not 
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displaying enzymatic activity, does obviously not interfere with their potent T cell 
stimulatory capacity. 
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Zusammenfassung 
Die Expression des Tryptophan (TRP)-abbauenden Enzyms Indolamin 2,3-
Dioxygenase (IDO) in bestimmten Typen von dendritischen Zellen (DCs) wurde mit 
Suppression T-Zell-vermittelter Immunantworten und damit auch mit der Suppression 
der immunologischen Kontrolle von Krebszellen in Verbindung gebracht. In dieser 
Studie haben wir untersucht, ob die T-Zell-stimulierende Kapazität von DCs, die aus 
murinen hämatopoietischen Stammzellen generiert wurden (HSC-derived DCs), 
durch die Aktivität von IDO beeinflusst ist. 
Wir zeigen, dass HSC-derived DCs von C57BL/6 Mäusen nach Aktivierung mit 
Lipopolysacchariden (LPS) und Interferon-gamma (IFN-γ) sowohl die Expression von 
CD80, CD86, Haupthistokompatibilitätskomplex Klasse II (MHC class II) und CD40, 
als auch die Sekretion von T Helferzellen 1 (Th1) induzierenden Zytokinen 
hochregulierten und damit einen aktivierten Phänotyp aufwiesen. Während LPS und 
IFN-γ stimulierte humane DCs IDO Aktivität aufzeigten, zeigten murine HSC-derived 
DCs keinen Tryptophan-Abbau, obwohl die Boten-Ribonukleinsäure (mRNA) des 
IDO-Gens erhöht vorlag. Um auszuschließen, dass die vermehrte Gen Transkription 
immer noch in einer für die Detektion der enzymatische Aktivität zu geringen Protein-
Expression resultierte, wurden HSC-derived DCs mit einem IDO-Expressionsvektor 
transfektiert. Trotz signifikanter und stabiler Überexpression von IDO mRNA und 
Protein zeigten diese Zellen keine IDO Aktivität. Um die immunstimulierende 
Kapazität dieser DCs zu untersuchen wurden Ko-Kulturen mit T Zellrezeptor-
transgenen, Ovalbumin (OVA) spezifischen CD4 (OT-2) oder CD8 (OT-1) T Zellen 
durchgeführt. Erwartungsgemäß zeigten diese Experimente kräftige T-Zell-
Antworten, die proportional mit der Anzahl der eingesetzten OVA-Peptid beladenen 
DCs zusammenhängten. LPS und IFN-γ Stimulierung von HSC-derived DCs 
aktivierte auch die induzierbare Stickstoffmonoxid –Synthase (iNOS) und damit die 
Produktion von NO, das als starker Inhibitor der IDO Aktivität beschrieben worden ist. 
NO Konzentrationen in unseren Kulturen waren mit jenen Werten vergleichbar, die 
die IDO Aktivität in anderen Studien inhibierten. Interessanterweise konnte keine 
iNOS Aktivität in verschiedenen murinen (Raw264.7 und J558) und humanen 
(Phoenix und HeLa) Zelllinien nachgewiesen werden, die nach Transfektion mit dem 
äquivalenten IDO-Gen effiziente IDO Aktivität aufwiesen. 
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Zusammenfassend deuten diese Daten darauf hin, dass murine HSC-derived DCs 
IDO in einer enzymatisch inaktiven Form halten. Die IDO Expression in seiner 
inaktiven Form scheint die potente T-Zell-stimulierende Kapazität von murinen HSC-
derived DCs nicht zu beeinträchtigen.  
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Introduction 
Induction of T cell tolerance and immune evasion are essential mechanisms that 
counteract effective immunity which would otherwise result in dangerous collateral 
damage to the host (Munn 2006). In recent years, increasing evidence has been 
accumulated that antigen presenting cells (APCs) such as DCs play a major role in 
induction, but also in inhibition of immune responses (Banchereau and Steinman 
1998; Steinman 2003). Converting DCs from stimulatory to regulatory cells involves a 
variety of molecular mechanisms. The TRP catabolizing enzyme IDO has been 
proposed as a key molecule for immuno-suppressive DCs. Its potential responsibility 
for impaired T cell responses has positive and negative implications (Rutella, Danese 
et al. 2006). On the one hand IDO is essential for successful allogeneic pregnancy in 
mice (Munn, Zhou et al. 1998) and inhibition of proliferation of tryptophan sensitive 
pathogens (Yoshida, Urade et al. 1979; Rottenberg, Gigliotti Rothfuchs et al. 2000; 
Hayashi, Rao et al. 2001; Fujigaki, Saito et al. 2002), but on the other hand the 
enzyme is thought to impede immunological cancer control (Friberg, Jennings et al. 
2002; Uyttenhove, Pilotte et al. 2003). Anti-tumor DC vaccines that prime anti-tumor 
specific T cells are intensively tested for their potential to supplement conventional 
chemotherapy. Early clinical trials in humans showed that DC vaccination appeared 
to be safe, but that only occasionally significant tumor regression was yielded 
(Banchereau and Palucka 2005; Zou 2005; Steinman and Banchereau 2007). Given 
its proposed role as a key molecule in immuno-suppression, recent reports focused 
on evaluation of IDO in these immunotherapeutic strategies (Wobser, Voigt et al. 
2007; Ou, Cai et al. 2008). 
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Biology of IDO 
IDO mechanism 
TRP belongs to the least abundant of the essential amino acids (AAs) and as a 
consequence, TRP deficiency is easily attained. In the mammalian system several 
pathways exist that metabolize TRP (Figure 1). Most commonly known is the 
conversion of TRP into serotonin which involves 1% of the total body TRP content. 
More than 95% of TRP are converted through the KYN pathway (Takikawa 2005). In 
mammals, two known enzymes are involved in the catalysis of the first and rate 
limiting step in the Kynurenine (Kyn) pathway. The first, termed tryptophan 2,3-
dioxygenase (TDO, EC 1.13.11.11), was identified in the liver in 1937 (Kotake and 
Masayama 1937). Decades later, the second TRP-degrading enzyme, IDO (EC 
1.13.11.52), was identified in rabbit intestine (Yamamoto and Hayaishi 1967).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tryptophan
3-hydroxykynurenine
Kynurenine
Anthranilic acid
NAD
Quinolinic acid
3-hydroxyanthranilic acid
TDOIDO
Serotonin
 
 
Figure 1: The major metabolic pathway of TRP. 
IDO catalyzes the initial and rate-limiting step in the degradation of TRP along the 
Kyn pathway. Chemical structures taken from (Zhang, Kang et al. 2007). 
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IDO and TDO are cytosolic monomeric heme-containing dioxygenases that 
oxidatively cleave the 2,3 double bond in the indole ring of TRP upon incorporation of 
two oxygen atoms of O2 which results in the production of N-formylkynurenine 
(Shimizu, Nomiyama et al. 1978). N-formylkynurenine is subsequently metabolized 
into other downstream molecules, including 3-hydroxyanthranilic acid, kynurenate 
and quinolinate, to predominantly generate nicotinamide adenine dinucleotide (NAD) 
(Takikawa, Yoshida et al. 1986). 
Although both enzymes are responsible for the initial degradation step in the TRP 
metabolism, they are distinct. In mammals, TDO is only found in the liver, whereas 
IDO is distributed in various nonhepatic organs, e.g. lung, placenta or brain (Yoshida, 
Nukiwa et al. 1980). IDO can also be found in a variety of murine tumor cells 
(Habara-Ohkubo, Takikawa et al. 1991). Most importantly, IDO can be expressed in 
different APCs, e.g. DCs (Alberati-Giani, Ricciardi-Castagnoli et al. 1996; Fallarino, 
Vacca et al. 2002). IDO has a wider substrate spectrum, including many indoleamine 
derivatives like L- and D-tryptophan, tryptamine, 5-hydroxytryptophan, and serotonin 
(Taylor and Feng 1991). Moreover and of crucial importance, TDO steady-state 
activity is observed in homeostatic conditions, whereas IDO activity appears to be 
regulated in a dynamic fashion, i.e. it is enhanced in an inflammatory environment 
(Yamamoto and Hayaishi 1967). 
The early literature documented that IDO is part of the cellular host defense against 
certain pathogens that depend on exogenous TRP and are thus sensitive to TRP 
depletion by IDO activity. The induction of IDO activity and hence depletion of TRP 
was implicated in the suppression of various pathogens. These included viruses 
(Yoshida, Urade et al. 1979) and pathogens which invaded cells or remained in 
intimate proximity to a host cell, such as Chlamydia pneumonia (Rottenberg, Gigliotti 
Rothfuchs et al. 2000), Toxoplasma gondii (Fujigaki, Saito et al. 2002) or 
mycobacteria (Hayashi, Rao et al. 2001). The role of IDO was profoundly 
reconsidered after Munn et al. reported that placental IDO activity was crucial to 
protect the fetus by suppressing T cell–driven local inflammatory responses to fetal 
alloantigens and that pharmacologic inhibition of IDO induces fetal rejection (Munn, 
Zhou et al. 1998). In the past years, the potential immuno-suppressive role of IDO 
was supported by in vitro and in vivo studies which suggested that IDO induced TRP 
depletion by APCs suppressed T cell responses (Mellor and Munn 2004) and that 
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IDO expressing islets inhibited T cell mediated rejection of allografted pancreas islets 
in mice (Alexander, Crawford et al. 2002) 
 
Regulation of IDO protein expression 
Murine IDO is a 407 AA long protein (MW 45,639 kilodalton (kDa)) encoded by a 
single gene, termed Indo, located on the chromosome 8. The cDNA was first isolated 
in 1991 from different cell lines upon exposure to IFN-γ and showed 62.5% homology 
to human IDO (Habara-Ohkubo, Takikawa et al. 1991). Various studies have 
demonstrated that IDO induction occurs in response to toll like receptor (TLR) 
ligands, e.g. bacterial endotoxin (lipopolysaccharide, LPS) (Yoshida and Hayaishi 
1978) or viruses (Yoshida, Urade et al. 1979), as well as by pro-inflammatory 
cytokines, including IFN-γ or tumor necrosis factor (TNF) (Bianchi, Bertini et al. 
1988). It is generally accepted that IFN-γ is one of the most important inducers of 
IDO (Fujigaki, Saito et al. 2002) and that induction is mediated through the 
JAK/STAT, in an IFN regulatory factor 1 (IRF1)- and signal transducer and activator 
of transcription 1 (STAT1)-dependent pathway (Du, Sotero-Esteva et al. 2000; Silva, 
Rodrigues et al. 2002). 
 
Regulation of IDO activity 
It is crucial to mention that IDO expression does not necessarily mean activity. 
Constitutive IDO expression is found in various types of DCs, but for enzyme activity 
further stimulatory signals are needed (Grohmann, Bianchi et al. 2000). Mechanisms 
that enable enzyme activity are poorly understood, but protein modifications on 
posttranslational level are suggested.  
IDO contains a protoheme IX as its sole prosthetic group that seems to be essential 
for enzyme activity. Normally, inactive IDO contains the heme present as ferric-iron 
(Fe3+) that needs to be reduced to the ferrous state (Fe2+) for enzyme activation. 
When the ferric enzyme is reduced by co-factors to the ferrous state it binds TRP and 
O2 to form the ternary complex (TRP-Fe2+-O2) (Sono, Taniguchi et al. 1980; Sono, 
Roach et al. 1996). The intracellular co-factors required for IDO heme-iron reduction 
are unknown. Putative candidates include superoxide anion radical, dihydroflavin 
mononucleotide, tetrahydrobiopterin and cytochrome reductases (King and Thomas 
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2007). In vitro, a combination of methylene blue (a redox dye) with ascorbic acid was 
suggested for activating IDO, whereby methylene blue reduces the molecular oxygen 
to superoxide anion (O2-) which, in turn, reduces the ferric form of IDO to the ferrous 
form (Takikawa 2005). 
Additionally, negative regulation of IDO on the posttranslational level by anti-oxidants 
(Thomas, Salahifar et al. 2001) or nitric oxide (NO) generators was reported. 
Whereas anti-oxidant pyrrolidine dithiocarbamate and heme biosynthesis inhibitors 
limit the availability of heme, NO generated by iNOS blocks the heme site to O2 
binding. NO induces conformational changes by breaking the Fe-N bond resulting in 
enzyme inactivity without reduction of protein quantity (Oh, Pae et al. 2004; Wood 
and Sawitzki 2006; Hara, Ogasawara et al. 2008).  
 
Implication of IDO activity 
There is evidence that IDO activity influences a variety of physiological and 
pathological conditions in vivo. Whereas IDO induced immuno-suppression is 
desirable in situations like murine pregnancy (Munn, Zhou et al. 1998), 
transplantation (Miki, Sun et al. 2001; Alexander, Crawford et al. 2002) or 
autoimmune syndromes (Sakurai, Zou et al. 2002), enzyme activity in others, e.g. 
malignancies (Friberg, Jennings et al. 2002; Uyttenhove, Pilotte et al. 2003) that 
implicates a worse clinical outcome, is unwanted. 
Two theories have been proposed that explain the immunological influence of 
enhanced TRP metabolism by IDO activity (Moffett and Namboodiri 2003). The TRP 
depletion theory postulates that TRP breakdown suppresses T cell proliferation by 
markedly reducing the supply of this critical AA. This theory was supported by studies 
that induced tolerance in activated T cells in vitro after TRP decrease below 0.5–
1 μM from the culture medium by IDO expressing DCs (Munn, Shafizadeh et al. 
1999). It has been reported that in these TRP-free culture media activated T cells 
entered the cell cycle, but halted proliferation at the mid-G1 phase (Lee, Park et al. 
2002). The second theory (TRP utilization theory) posits that the downstream 
metabolites of the TRP metabolism suppress certain immune cells, as shown in an in 
vitro study where TRP metabolites induce T cell apoptosis (Fallarino, Grohmann et 
al. 2002). 
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IDO in DCs 
It is widely accepted that the DCs (Figure 2) are the most potent and versatile APCs 
that are capable to induce adaptive immune responses (Steinman and Witmer 1978; 
Kapsenberg 2003; Reis e Sousa 2006).  
 
 
 
 
 
 
 
 
 
DCs are generated in the bone marrow and migrate as precursor cells to sites of 
potential entry of pathogens (Steinman, Lustig et al. 1974; Kapsenberg 2003). This 
not only includes nonlymphoid organs like epithelia, dermis and the interstitial of 
vascularised organs such as heart and kidneys, but also lymphoid organs or the 
blood and lymph (Reis e Sousa, Sher et al. 1999).  
It was first claimed by Steinman and colleagues that DCs exist in two functional 
states, immature and activated. In a quiescent immature state, DCs play a critical role 
in establishing tolerance to self antigen (Steinman and Nussenzweig 2002). In the 
periphery, they induce deletion or anergy in self-reactive T cells or expansion of 
regulatory T cells. Only in the activated state DCs have the ability to drive clonal T 
cell expansion and prime immune responses. These DCs are referred to as 
immunogenic DCs. Upon their activation a complex activation program is triggered 
that results in up-regulation of MHC class I and class II and co-stimulatory molecules, 
and production of cytokines. Moreover, they migrate to lymphoid organs, such as 
spleen and lymph nodes, where processed antigens are presented to activate 
antigen specific T cells (Cella, Sallusto et al. 1997; Banchereau and Steinman 1998). 
 
 
Figure 2: Dendritic cell. 
First visualized as Langerhans cells in the skin in 1868 
(Langerhans 1868), the characterization of DCs began only 35 
years ago (Steinman and Cohn 1973).One of the first images 
ever made of a DC was published by Steinman in 1974, who 
dubbed them dendritic cells, derived from the Greek word for 
tree. Picture taken from (Steinman 2007). 
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Recently, it was proposed that DC activation and the IDO pathway, as one of the 
negative feedback mechanisms, are initiated simultaneously (Hainz, Jurgens et al. 
2007), rendering DCs tolerogenic. On the one hand, negative regulatory pathways 
are important in the immune system to limit intensive and strong immune responses, 
which would otherwise result in dangerous collateral damage to the host. Some 
studies have shown that blocking of IDO led to a significant exacerbated 
inflammation and sometimes lethality during local inflammation (Gurtner, Newberry et 
al. 2003). On the other hand, negative regulatory responses in an immunological 
tumor environment would result in tumor progression. Whether IDO expression in 
tumor cells or in tumor associated DCs account for tumor progression is still under 
debate. 
 
Murine DC subtypes 
A variety of DCs described in lymphoid and non-lymphoid organs can be classified 
into at least six mouse DC subtypes (Table 1). DCs in the spleen can be divided into 
CD8- and CD8+ subsets, whereas CD8- DCs can further be subdivided into CD4- and 
CD4+ DCs. In the thymus, CD8+ DCs are supposed to be the main DC subtype. The 
lymph node additionally harbors DCs that express CD205. In non-lymphoid organs 
like the skin Langerhans cells have been observed. Recently, plasmacytoid DCs 
(pDCs) were found in all lymphoid organs (Shortman and Liu 2002; Ardavin 2003). 
 
 
 
 
 
 
 
Originally, it was assumed that DCs derive from common myeloid precursors due to 
their functional, phenotypic and morphological similarities to macrophages (van Furth 
and Cohn 1968). This concept has been confirmed by DCs generated from bone 
marrow proliferating MHC class II negative precursors in presence of granulocyte-
 
Table 1 Lymphoid tissues distribution of mouse DC subtypes. 
The terms “lymphoid” and “myeloid” DCs no longer denote hematopoietic origin, but are still 
commonly used. The table and values for steady-state, uninfected laboratory mice are based on 
the publication of (Shortman and Liu 2002). 
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macrophage colony-stimulating factor (GM-CSF) (Inaba, Inaba et al. 1992) and 
additionally strengthened by studies with human (Sallusto and Lanzavecchia 1994) 
and murine monocytes (Randolph, Inaba et al. 1999). The first assumption that DCs 
might be related to the lymphoid lineage came from the finding that the typical 
lymphoid marker CD8 was expressed on mouse thymic DCs and on a subset of 
splenic DCs (Vremec, Zorbas et al. 1992). Transfer experiments with thymic 
lymphoid precursors that fully reconstituted the thymic CD8α+ DC population 
(Ardavin, Wu et al. 1993; Ardavin 1997) supported the hypothesis that CD8α- DCs 
are of myeloid origin and CD8α+ DCs of lymphoid origin (Wu, Li et al. 1996). Today it 
is known that both subsets can be generated from common lymphoid or myeloid 
precursors (Martin, del Hoyo et al. 2000; Traver, Akashi et al. 2000). The last DC 
subtype completing the list is murine pDCs. The first evidence for these cells came 
from DC-studies that solely secreted IFN-alpha and IL-12 upon virus challenge, but 
not upon treatment with bacterial products (Asselin-Paturel, Boonstra et al. 2001). 
Even though different DC subtypes share the common capacity to present antigen to 
T cells and to promote their proliferation, none of them is a product of the other and 
all are short-lived products (Kamath, Pooley et al. 2000). In vitro studies indicate that 
any of the DC subtypes can functionally divide into either immunogenic or tolerogenic 
DCs. Factors determining the DC phenotype include the activation state of the DCs, 
type and concentration of antigen/microorganism invading a host thereby restricting 
the DC subtype available in the specific tissue, the type of receptor responsible for 
antigen uptake and the genetic background of the host (Abbas, Murphy et al. 1996; 
Moser and Murphy 2000; Ardavin 2003). For instance, CD8+ DCs have the ability to 
induce strong Th1 response, representing immunogenic DCs (Maldonado-Lopez, De 
Smedt et al. 1999). Interestingly, IDO activity in the same DC subtype was implicated 
in enhanced apoptosis of CD4 T cells. Consequently, they might also belong to a 
specialized subset of tolerogenic or regulatory DCs (Kronin, Winkel et al. 1996; 
Grohmann, Fallarino et al. 2001). 
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Immunogenic DCs 
Pathogen primed activated DCs can readily prime naïve T cells (Figure 3). Their fate 
is determined by three signals that are provided by the DCs. Signal 1 stimulation 
results from the ligation of TCRs with pathogen-derived peptides bound to respective 
MHC on the DC surface and defines the antigen specificity of the response. Induction 
of clonal T cell expansion, development into effector T cells and thus protective 
immunity, requires stimulation through signal 1 and co-stimulation through signal 2 
(CD80/CD86). Typically, these two signals are accompanied by high level secretion 
of selective sets of cytokines – signal 3 – determining effector cell differentiation 
(CD4 Th1, CD4 Th2 and cytotoxic CD8 T-lymphocyte (CTL)) (Kapsenberg 2003; Reis 
e Sousa 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
Activation of DCs and initiation of the immune system 
More than 15 years ago, two major models proposed that resting DCs can be 
activated by signals from their immediate environment. In Janeway`s Infectious-
Nonself model, DC activation was suggested to be induced by direct recognition of 
exogenous signals (produced by different organisms), known as pathogen-
associated molecular patterns (PAMPs) through a series of germline-encoded 
 
 
Figure 3: For T cell activation and thus polarization 3 signals are mediated by the DC, 
including the antigen-specific signal (Signal 1), the co-stimulatory signal (Signal 2) and the 
polarizing signal (Signal 3). IFN-γ, interferon-gamma; PAMPs, pathogen-associated 
molecular patterns; PRR, pattern-recognition receptors; T cell receptor, TCR; TFs, 
inflammatory tissue factors; TH1/2, T helper cell 1/2; TNF-β, tumor-necrosis factor-beta 
(Kapsenberg 2003). 
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pattern-recognition receptors (PRRs) (Janeway 1989). As a result, DCs are able to 
discriminate between “infectious-nonself” and “noninfectious-self” (Janeway 1992). 
An important group of PRRs, Toll, was first identified in Drosophila as an essential 
molecule for embryonic patterning (Hashimoto, Hudson et al. 1988) and in antifungal 
immunity (Lemaitre, Nicolas et al. 1996). Later, the homologous family of Toll 
receptors, the so called TLRs were found in mammals (Medzhitov, Preston-Hurlburt 
et al. 1997). The TLRs are type I transmembrane glycoproteins (Akira and Takeda 
2004) and signal through a pathway that mostly leads to activation of NFkB, a family 
of transcription factors that seems to be implicated in many inflammatory responses 
(Gay and Keith 1991). Currently, twelve members of the TLR family in mice are 
known (TLR1-TLR9, TLR11-TLR13). Each of them recognizes specific patterns of 
microbial components (Takeda and Akira 2007). For example, TLR4 is triggered by 
LPS, a cell wall component of gram-negative bacteria (Medzhitov, Preston-Hurlburt et 
al. 1997); TLR3, by PolyIC, a synthetic double stranded ribonucleic acid (dsRNA) 
(Alexopoulou, Holt et al. 2001); and TLR7, by imidazoquinoline resiquimod (R848) 
(Heil, Ahmad-Nejad et al. 2003). 
In contrast, Matzinger`s Danger model suggested that DCs can be activated through 
endogenous danger signals (produced by the same organism) normally sequestered 
in intracellular compartments (Matzinger 1994). A study by Gallucci and colleagues 
revealed that in absence of foreign substances DCs could neither be activated by 
healthy cells nor by those dying of apoptosis, but through signals from stressed or 
virally infected or necrotic cells instead (Gallucci, Lolkema et al. 1999). This response 
includes the production of IFNs by virally infected cells in response to dsRNA; TNF-α, 
interleukin-1β (IL1β) and IL18 by keratinocytes (Winzler, Rovere et al. 1997); heat 
shock proteins by necrotic cells (Basu, Binder et al. 2000); and also CD40L 
expressed on activated T- and many other cells (Caux, Massacrier et al. 1994; 
Sallusto and Lanzavecchia 1994; Cella, Scheidegger et al. 1996). 
 
Antigen presentation by DCs – Signal 1 
The initiation of antigen-specific immune responses requires the conversion of 
proteins into peptides that bind to MHC molecules (Germain 1994). Intracellularly 
synthesized antigens (of viral or tumor origin) are presented by MHC class I 
molecules and activate CTLs. The generation of activated, peptide-loaded MHC 
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class I molecules at the cell surface requires the co-ordination of three essential 
processes (Lehner and Cresswell 1996). Firstly, proteins need to be degraded in the 
cytosol into antigenic peptides that are 8-11 AA long (Groettrup, Soza et al. 1996). 
This is a continuous process in all eukaryotes to eliminate damaged and unfolded or 
incomplete protein (Glickman and Ciechanover 2002), mainly by the ubiquitin-
proteasome pathway (Wilkinson, Urban et al. 1980). Secondly, antigens need to be 
translocated across the endoplasmic reticulum membrane and thirdly, they need to 
be assembled with MHC class I heterotrimers for their subsequent transport to the 
cell surface. Extracellular antigens are presented by MHC class II molecules to 
activate CD4 Th cells (Cresswell 1996). They enter the endocytic route of APCs by a 
variety of mechanisms: pinocytosis, phagocytosis, receptor-mediated endocytosis or 
autophagocytosis (Watts 1997). The generation of antigenic bound MHC class II 
molecules also involves three essential processes. Firstly, the MHC heterodimers 
need to be associated to the invariant chain. Secondly, they are transported to 
specialized lysosme compartments where they, thirdly, bind to lysosomally generated 
antigens that are 9-30 AA long (Miyazaki, Wolf et al. 1996). Subsequently, the MHC 
class II-peptide complexes are transported to the cell surface. A further mechanism 
that has been studied extensively is termed cross-presentation which permits 
extracellular antigen to stimulate CTLs via the MHC class I pathway (Mellman and 
Steinman 2001). Tumor antigens are exogenous antigens which would otherwise fail 
to induce CTL activity. Therefore, cross-presentation, hence presentation of 
exogenous tumor antigens to CD8 T cells, is an essential mechanism for cancer 
treatment with anti-tumor DC vaccines (Bhardwaj 2001).  
 
Co‐stimulatory signals – Signals 2 
Signal 1 in absence of signal 2 delivered by immature DCs promotes T cell deletion 
or anergy which might lead to tolerance (Steinman and Nussenzweig 2002). To 
induce immunity also signal 2 – the co-stimulation signal molecules expressed on cell 
surface of APCs – must be provided together with signal 1 (Reis e Sousa 2006). 
The B7-1/B7-2 – CD28/cytotoxic T-lymphocyte antigen-4 (CTLA-4) co-stimulatory 
pathway is best characterized and includes two B7 family members, B7-1 (CD80) 
(Freeman, Gray et al. 1991; Larsen, Ritchie et al. 1992) and B7-2 (CD86) (Freeman, 
Borriello et al. 1993) expressed on DCs. They have dual specificity for two CD28 
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family members, the stimulatory receptor CD28 (Gross, St John et al. 1990; June, 
Ledbetter et al. 1990) and the inhibitory receptor CTLA-4 (CD152) (Brunet, Denizot et 
al. 1987). Whereas CTLA-4 expression is up-regulated upon T cell activation 
(Linsley, Bradshaw et al. 1996), CD28 is constitutively expressed on the surface of T 
cells (Gross, Callas et al. 1992). B7-1 and B7-2 interaction with CD28 transmits a 
signal that synergizes with the TCR signal to augment and sustain T cell activation 
initiated by antigen-receptor signaling (Shahinian, Pfeffer et al. 1993). In contrast, B7-
1 and B7-2 interaction with CTLA-4 in various DC subtypes was implicated with an 
IDO dependent tolerogenic DC phenotype (Grohmann, Bianchi et al. 2003). 
 
T cell polarization – Signal 3 
Migrating DCs not only carry antigenic (Signal 1) and co-stimulatory signals (Signal 
2), but they are also well equipped to transmit an additional signal 3 to contribute to 
the polarization of naïve Th cells towards Th1 or Th2, supporting cell-mediated and 
humoral immunity respectively (Kalinski, Hilkens et al. 1999).  
The classification of these two cell populations on the basis of their patterns of 
cytokine production was first shown by Mosmann and colleagues. By analyzing Th 
cell clones they characterized Th1 clones by their production of IL2, IFN-γ and TNF-
β, and Th2 clones by IL4, IL5, IL6 and IL13 (Mosmann, Cherwinski et al. 1986). 
Shortly after, it was realized that the function of Th1 and Th2 cells correlated with 
their distinctive cytokines. Whereas Th1 cytokines promote cell-mediated immunity 
by activating cytotoxic functions in effector cells such as CTLs, natural killer cells and 
macrophages, Th2 cytokines support humoral immunity by inducing B cell production 
of AG-specific antibodies (Abs). These secreted cytokines also serve as autocrine 
growth factors that promote differentiation of naïve T cells to the same subset and 
also cross-regulate each other`s development and activity, e.g. inhibited Th2 cell 
proliferation by IFN-γ or Th1 by IL10 (Mosmann and Sad 1996). The key Th1 and 
Th2 inducing cytokines secreted by APCs were defined through experiments with IL-
12 (Magram, Connaughton et al. 1996) and IL4 (Kopf, Le Gros et al. 1993) knockout 
mice respectively.  
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IL‐12 cytokine 
IL-12 secretion by DCs represents highly immunogenic Th1 polarizing cells and 
detection of IL-12 in our study is used to determine this DC phenotype. The cytokine 
was first discovered in human B lymphoblastoid cells (Kobayashi, Fitz et al. 1989) 
and a few years later in murine DCs (Trinchieri 1994; Macatonia, Hosken et al. 1995; 
Heufler, Koch et al. 1996). The bioactive form of IL-12 is a 70 kDa heterodimeric 
protein composed of two disulfide-linked subunits designed p35 (35-kDa) and p40 
(40-kDa) which reside at independent loci in the murine genome on chromosome 3 
and 11, respectively (Schoenhaut, Chua et al. 1992). The 40 kDa fragment is formed 
exclusively in DCs, macrophages and monocytes and produced in excess of the 35 
kDa subunit. To generate the bioactive form, both subunits need to undergo post-
translational modification and dimerization within the same cell (Wolf, Temple et al. 
1991; Babik, Adams et al. 1999). IL-12 secretion by DCs can be induced in response 
to conventional stimuli such as LPS or with IFN-γ (Abdi, Singh et al. 2006), PolyIC 
(Heufler, Koch et al. 1996) or by ligation of CD40 (Koch, Stanzl et al. 1996). Its 
secretion, however, is only a transient process that induces strong Th1 polarization at 
early time points after DC activation, and that primes Th2 or nonpolarized cells at 
later times points (Langenkamp, Messi et al. 2000).  
 
Licensing signal – for effector function of CTLs 
CTLs are responsible for the recognition of peptide antigens presented by MHC class 
I molecules and subsequent lysis of these antigen-bearing target cells, e.g. tumor 
cells. To enable priming of CTLs for extracellular tumor antigens, interaction of Th 
cells with DCs is required (Guerder and Matzinger 1992). CD40 and CD40 ligand 
(CD40L) were identified as responsible molecules for the proposed mechanism. In 
these in vivo and in vitro studies it was reported that mice lacking Th cells could only 
regain CTL response upon substitution of an agonistic Ab to CD40 and that blocking 
CD40L signaling inhibits CTL priming (Bennett, Carbone et al. 1998; Ridge, Di Rosa 
et al. 1998; Schoenberger, Toes et al. 1998).  
CD40L is a 39 kDa type II membrane protein that is preferentially expressed on 
activated CD4 T cells. The receptor for CD40L, CD40 (40 kDa), is a phosphorylated 
50 kDa glycoprotein that is expressed on mature B cells, vascular endothelial cells, 
monocytes/macrophages, Langerhans cells and DCs (Armitage, Fanslow et al. 1992; 
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Caux, Massacrier et al. 1994; Stout and Suttles 1996; Grewal and Flavell 1998). 
Interaction of CD40L with CD40 on DCs induces up-regulation of T cell co-stimulatory 
molecules and release of cytokines that favor Th1 development which consecutively 
stimulate generation of CD8 CTLs (Cella, Scheidegger et al. 1996). 
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Tolerogenic DCs in malignancies 
During tumor development, referred to as cancer immunoediting, the surviving tumor 
variants acquire insensitivity to immunologic detection and/or elimination and thus 
can escape immune surveillance. In the elimination phase, cells of the innate and 
adaptive immune system help to destroy the developing tumor cells. In the 
equilibrium and escape phases, on the contrary, tumor cells that carry different 
mutations arise, which are more resistant to immune attack and thus begin to expand 
in an uncontrolled manner (Dunn, Bruce et al. 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
Tumor progression and escape in patients was (among other mechanisms) shown to 
be associated with secretion of immuno-suppressive factors by the tumor itself that 
contribute to proliferation and survival of malignant cells (Yu and Jove 2004) or 
secretion of tumor-derived factors that alter immunogenic DCs to become tolerogenic 
(Pinzon-Charry, Maxwell et al. 2005). These emerging tolerogenic factors may 
contribute to block the initial response to tumor antigens (Staveley-O'Carroll, 
Sotomayor et al. 1998), inhibit the ability of activated T cells to kill tumor cells 
(Gajewski, Meng et al. 2006) and enhance the suppressive activity of regulatory T 
cells (Zou 2006). As a consequence, the immune system is no longer optimally 
 
 
Figure 4: Two possible sites for the immuno-suppressive action of 
IDO in tumor-bearing hosts. 
IDO (red arrows) expressed by tumor cells themselves could create a 
localized milieu of immuno-suppression in the tumor (right). Alternatively, 
DC expressing IDO could pick up tumor-derived AG (green spheres) and 
migrate to tumor-draining lymph nodes, in which they would present 
antigen to naïve T cells (left) (Munn and Mellor 2004). 
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activated and fails to reject the tumor (Gilboa 2004; Gilboa 2007; Steinman and 
Banchereau 2007). 
One of the immuno-suppressive factors expressed in both, tumor cells and DCs, and 
that might contribute to this tolerance is the immuno-regulatory enzyme IDO (Figure 
4). The immuno-suppressive role of IDO expression in tumor cells was supported by 
human and murine studies. In primary human tumors it was observed that expression 
of IDO (e.g. malignant melanoma, ovarian carcinoma, endometrial cancer and colon 
carcionma) was associated with a markedly worse clinical outcome (Lee, Torisu-
Itakara et al. 2005; Okamoto, Nikaido et al. 2005; Brandacher, Perathoner et al. 
2006; Ino, Yoshida et al. 2006). In pre-immunized mice IDO transfection in IDO-
negative tumor cells protected the tumor from immune-mediated rejection 
(Uyttenhove, Pilotte et al. 2003) and IDO silencing in IDO-positive murine tumor cells 
resulted in recovery of T cell response and enhanced tumor-specific killing (Zheng, 
Koropatnick et al. 2006; Muller, Sharma et al. 2008). However, it is not clear whether 
local TRP depletion by tumor cells could suppress systemic immune responses to 
tumor AGs. In addition, TRP depletion would tend to have an anti-proliferative effect 
on the dividing tumor cells (Taylor and Feng 1991). Interestingly, a recent publication 
suggested that TRP metabolize dependent DC self-starvation is protected by 
simultaneous expression of tryptophanyl-tRNA-synthetase that accumulates TRP in 
human DCs (Boasso, Herbeuval et al. 2005). Based on these data, tumor-associated 
DCs expressing IDO in addition to tumor cells would be ideally positioned to control 
responses to tumor AG (Grohmann, Fallarino et al. 2001). 
 
IDO in DC subtypes 
IDO does not appear to be critical for maintaining constitutive tolerance, as IDO 
deficient mice lack the generation of a spontaneous autoimmune phenotype. 
However, involvement in certain types of immune regulation, e.g. in certain organs 
(Chen, Liu et al. 2006), tolerance after transplantation (Grohmann, Orabona et al. 
2002), or during pregnancy (Munn, Zhou et al. 1998) appear to be the case. The first 
hint for a role of IDO in DCs was shown in a study with human cells that suppressed 
T cell proliferation in vitro (Hwu, Du et al. 2000). Recent in vivo and in vitro reports 
support a general immuno-suppressive role of IDO expressing cells at least in distinct 
subtypes of murine DCs (Mellor and Munn 2004; Popov and Schultze 2008). 
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Extensive studies have been carried out on the potential immuno-suppressive role of 
IDO in CD8+ and CD8- splenic DCs. It was reported that IFN-γ treatment of CD8+ or 
CD8- splenic DCs up-regulated IDO protein and mRNA in vitro. Only in the CD8+ 
splenic DCs subset, active IDO expression and enhanced apoptosis in CD4 T cells 
was observed (Fallarino, Vacca et al. 2002). Another publication by the same authors 
suggested that CD8+ splenic DCs mediated suppression of a delayed-type 
hypersensitivity response to tumor-antigens was dependent on IDO activity in vivo. 
IDO activity could be implicated in the immuno-suppressive properties of CD8+ 
splenic DCs, because Kyn accumulation was only seen with IFN-γ treated CD8+ 
splenic DCs, but not with IFN-γ treated CD8- splenic DCs or with any of the untreated 
splenic DCs in vitro. Additionally, treatment with 1-methyl-tryptophan (1-MT) (Cady 
and Sono 1991), a pharmacologic agent that blocks IDO activity, reversed apoptosis 
in CD4 T cells and suppression of delayed-type hypersensitivity responses 
(Grohmann, Bianchi et al. 2000; Grohmann, Fallarino et al. 2001; Grohmann, 
Fallarino et al. 2001). Reversion of the immuno-suppressive properties of CD8+ DCs 
into immunogenic DCs was also obtained after engagement of B7 with CD28-Ig or 
after CD40 cross-linking with CD40 mAb (Fallarino, Grohmann et al. 2002; 
Fallarino, Asselin-Paturel et al. 2004). Interestingly, the otherwise immunogenic CD8- 
DC subset has been reported to become tolerogenic upon B7-1 ligation of CLTA-4-
Immunoglobulin (Ig) (Grohmann, Bianchi et al. 2003).  
Studies with tumor-bearing mice showed that CD11c+ B220+ CD19+ pDCs, isolated 
from tumor-draining lymph nodes, but not from contralateral lymph nodes, actively 
suppressed T cell proliferation in vitro and induced antigen specific T cell anergy in 
vivo. None of these effects were seen when pDCs were treated with 1-MT or taken 
from IDO knock-out mice. Moreover, OT1 T cells from GCN2 knock-out mice, lacking 
a stress-response kinase that is activated by elevations in uncharged tRNA and 
suggested as a molecular sensor in T cells were refractory to IDO-induced anergy in 
a mixed lymphocyte reaction with IDO active pDCs from tumor draining lymph nodes 
(Munn, Sharma et al. 2004; Munn, Sharma et al. 2005). Delayed-type 
hypersensitivity studies with otherwise nontolerogenic CD11c+ B220+ 120G8+ splenic 
pDCs expressed active IDO and initiated immuno-suppressive responses after B7-1 
engagement with CLTA-4-Ig or after CD200-Receptor-1 engagement with CD200-Ig. 
Again, 1-MT was able to reverse the immuno-suppressive property of these pDCs. In 
the same studies it was suggested that CD200-Receptor-1 engagement with CD200-
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Ig contingent upon autocrine effects of type I IFNs and that B7-1 engagement with 
CLTA-4-Ig was IFN-γ dependent (Fallarino, Asselin-Paturel et al. 2004; Fallarino, 
Orabona et al. 2005). 
Up-regulated IDO protein and acquired potent T cell regulatory function was also 
detected in CD11c+ splenic DCs that co-expressed the marker CD19, but not in 
CD19- splenic DCs after injection of CLTA-4-Ig or CpG in vivo. In vitro mixed 
lymphocyte reactions of these in vivo CpG treated CD19+ DCs with T cells could be 
reversed by addition of 1-MT and the same DCs from IDO knock-out mice never 
acquired suppression. IDO expression in these cells was suggested to be type I IFN 
dependent (Baban, Hansen et al. 2005; Mellor, Baban et al. 2005). 
Only sparse information about IDO activity in HSC-derived DCs is available. In a 
study that examined this specific DC subtype in context of IDO mediated immuno-
suppression, up-regulation of the enzyme after treatment with LPS or IFN-γ was 
measured (Jung, Lee et al. 2007). A subsequent study revealed that the IFN-γ 
induced IDO expression and activity was associated with a suppressed proliferation 
of OT1 T cells in vitro. 1-MT was as well sufficient to enhance T cell proliferation. 
Interestingly, rosmarinic acid seemed to have the same effect as 1-MT in enhancing 
T cell proliferation (Lee, Jeong et al. 2007). 
 
DCs and their potential as anti‐tumor vaccines 
The idea that the immune system can be activated to recognize and respond to 
tumors was formed in the late 19th century when William Coley noticed that rare 
events of spontaneous tumor regression were often preceded by infections. 
However, attempts to stimulate systemic immunity directed against tumors with 
bacterial extracts had limited success (Nauts 1989). The finding that the immune 
system can respond to defined tumor-specific antigens (Van den Eynde and van der 
Bruggen 1997) together with the discovery of in vitro DC generation from murine 
hematopoietic stem cells (HSCs) (Inaba, Inaba et al. 1992), human CD34+ 
hematopoietic progenitors (Santiago-Schwarz, Belilos et al. 1992) and peripheral 
blood-derived monocytes (Romani, Gruner et al. 1994) introduced the era of ex vivo 
anti-tumor DC vaccines.  
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Today, anti-tumor DC vaccines are one of the strategies to supplement conventional 
chemotherapy (Banchereau and Palucka 2005; Zou 2005; Steinman and 
Banchereau 2007). For most studies ex vivo generated DCs are loaded with tumor-
specific antigens and activated with various stimuli. Subsequently, these cells are re-
injected (Figure 5), with the objective to induce a robust and long-lasting CD4 and 
CD8 T cell response against the tumor in cancer-bearing patients (Gilboa 2007). 
Studies in mice that effectively inhibited tumor growth in both prophylactic and 
therapeutic contexts using DCs loaded with tumor antigens endorsed the idea for 
anti-tumor DC vaccines (Celluzzi, Mayordomo et al. 1996; Zitvogel, Mayordomo et al. 
1996). Nevertheless, early clinical trials in humans showed that DC vaccination 
appeared to be safe, but that only occasionally significant tumor regression was 
yielded. As a consequence, improvements of therapeutic outcomes invoke the need 
to develop increasingly potent cancer vaccination strategies, e.g. optimal generation 
and activation of DCs, choice of antigen (peptides, proteins or whole tumor lysate), 
antigen-dose, -route and -frequency of DC delivery (Schuler, Schuler-Thurner et al. 
2003; Steinman and Banchereau 2007; Koski, Cohen et al. 2008). 
 
IDO as a possible target to improve anti‐tumor DC vaccines 
It is assumed that immunization with anti-tumor DC vaccines loaded with tumor 
antigens, against which tolerance has been established, could intensify antigen-
specific immuno-suppression (Zhou, Drake et al. 2006). Therefore, one of the most 
promising strategies to enhance DC immunogenicity is the down-regulation of 
 
 
Figure 5: Ex vivo loading of DCs with tumor antigens. 
DCs are loaded with defined tumor antigens or whole tumor lysat using various techniques at 
the immature stage to allow for efficient processing of the loaded antigen. Subsequently, DCs 
are activated ex vivo by incubation with various agents. CRT, calreticulin; ds, double stranded; 
HSP, heat-shock proteins; IL-1, interleukin-1; LPS, lipopolysaccharide; PGE2, prostaglandin E2; 
TNF-α, tumour-necrosis factor-alpha (Gilboa 2004). 
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negative feedback mechanisms in these cells that would otherwise dampen the 
immune response of a DC vaccine. It seems that IDO emerges as a potentially 
important immuno-suppressive factor in patients with cancer (Munn and Mellor 2007). 
Studies with IDO-deficient mice that exhibit a robust tumor-resistant phenotype in 
comparison to IDO-positive-wild type hosts IDO related immune-suppression is also 
suggested (Muller, Sharma et al. 2008). For this reason, conventional chemotherapy 
with concomitant inhibition of IDO in tumor bearing hosts should allow disruption of 
tolerance toward established tumors and trigger anti-tumor immune responses 
(Muller, DuHadaway et al. 2005; Hou, Muller et al. 2007).  
We are currently conducting a clinical trial where treatment with an anti-tumor DC 
vaccine loaded with tumor cell lysate from patients suffering from advanced solid 
pediatric malignancies are tested (Dohnal, Witt et al. 2007). At the same time, 
functionality of anti-tumor DC vaccines has been investigated using murine HSC-
derived DCs in prophylactic and therapeutic tumor models in vivo (Huttner, Breuer et 
al. 2005).  
In the current study we wanted to investigate whether IDO is actively expressed in 
murine HSC-derived DCs and potentially dampens an otherwise enhanced T cell 
stimulatory capacity of the anti-tumor DC vaccine. 
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Results 
Inactive IDO in murine HSC­derived and splenic DCs 
Studies have shown that the activation of DCs with selected stimuli results in IDO 
activity in certain DC subtypes (Popov and Schultze 2008). To investigate whether 
IDO activity in different DC subtypes can be induced, we used different stimuli to 
trigger IDO activity. First, we established the conditions to generate murine HSC-
derived DCs and in addition to enrich murine CD11c+ CD8+ and CD11c+ CD8- DC 
subsets from splenic cells. 
 
Generation of murine HSC­derived DCs 
 
 
 
 
 
 
 
 
 
For the generation of murine HSC-derived DCs, HSCs were differentiated with IL4 
and GM-CSF. After 6 days of culture, non adherent cells were harvested and tested 
by flow cytometry for expression of characteristic DC surface markers, hereafter 
referred to as day 6 HSC-derived DCs. Based on dose response curves 5 ng/ml IL4 
and 5 ng/ml, GM-CSF resulted in stable generation of HSC-derived DCs as identified 
by CD11b/c expression (data not shown). In several individual experiments, 
approximately 33±4% (mean±SD) of viable cells were positive for CD11b/c 
expression (Figure 6).  
 
 
Figure 6: CD11b/c expression by HSC-derived DCs. 
HSC were cultured with 5 ng/ml IL4 and 5 ng/ml GM-CSF. On day 
6 of culture non adherent cells were stained with isotype-matched 
(A) or anti-CD11b and CD11c mAb (B) and analyzed by flow 
cytometry. The diagram shows the analysis of viable cells.  
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Enrichment of CD8+ and CD8 splenic DCs 
 
 
 
 
 
 
 
 
As splenic DCs share expression of CD11c, this marker was used to enrich the cells 
by magnetic cell sorting. Typically, 3.4 x 106 cells per spleen were collected from 
which approximately 64±4.5% were positive for CD11c (Figure 7). CD11c+ splenic 
DCs were MACS separated into CD8+ and CD8- splenic DC subsets. The 
separated subsets typically contained 23±2.6% and 94±4% CD11c+ DCs, 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: CD11c expression by splenic DC subsets. 
DC purity was evaluated by flow cytometry analysis after CD11c MACS 
enrichment (CD11c+ DCs) and subsequent separation into CD8- (CD8-) 
and CD8+ splenic DCs (CD8+). Cells were stained with isotype-matched 
(dotted line) or anti-CD11c mAb (black lines). The diagram shows the 
analysis of viable cells and illustrates one representative experiment out 
of three. The bar indicates percentage of CD11c positive cells. 
 
 
Figure 8: Surface marker expression by splenic DC subsets. 
The same splenic DCs as described in Figure 7 were tested for the 
expression of additional cells surface markers. Cells were stained with 
isotype-matched (dotted lines) or anti-MHC class II, CD11b, CD3 and 
CD19 mAb (black lines). The diagram shows the analysis of viable cells 
and illustrates one representative experiment out of three. 
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The surface phenotype of CD11c+ splenic DCs and the CD8+ and CD8- DC 
subsets thereof were compared using different DC markers. In accordance with the 
literature, CD8+ splenic DCs expressed high levels of MHC class II and displayed 
low levels of CD11b (Figure 8), whereas CD8- splenic DCs expressed high levels of 
MHC class II and CD11b. About 25±3% of the cells in the CD8+ cell fraction showed 
CD8 expression. All splenic DC subsets were negative for CD3 and CD19 
expression, which are common T -and B-cell markers. 
 
Activation of HSC­derived and splenic DCs 
For IDO induction, day 6 HSC-derived DCs were sorted according to CD11c 
expression (day 6 CD11c+ HSC-derived DCs) and activated for 24 hours. Cells were 
activated with IFN-γ in combination with LPS or R848 or PolyIC. Alternatively, cells 
were exposed to IFN-γ in combination with CD40L transgenic J558 (J558L) cells or 
CD40 monoclonal antibody (mAb) for cross linking CD40 surface molecules. The 
purified CD8+ and CD8- splenic DC subsets were treated with IFN-γ alone for 24 
hours (Grohmann, Bianchi et al. 2000). 
 
Surface marker expression by activated HSC‐derived DCs 
Flow cytometry of CD11b/c positive HSC-derived DCs was used to analyze the 
expression density of CD80, CD86, CD40 and MHC class II before and 24 hours 
after exposure to the respective activation stimulus (Figure 9). 
Immature DCs were negative for CD40 and CD80 expression and displayed basal 
levels of CD86 and MHC class II. Activated DCs demonstrated low and strong 
expression of CD40 and CD80, respectively, and enhanced expression of CD86 and 
MHC class II. Expression was most pronounced in LPS/IFN-γ and R848/IFN-γ 
stimulated DCs. 
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Cytokine production by activated HSC‐derived and splenic DCs 
 
 
 
 
 
 
 
 
 
 
 
The ability of DCs to produce the Th1 cytokine IL-12p70 (mean±SD of three 
experiments) upon stimulation was determined by enzyme linked immunosorbent 
assay (ELISA) in the supernatants of the different DC cultures. No IL-12p70 was 
 
 
Figure 9: Surface marker expression by activated HSC-derived DCs. 
Day 6 CD11c+ HSC-derived DCs were triple stained with either isotype-controls (dotted lines) or 
anti-CD80, CD86, MHC class II or CD40 mAb in addition to anti-CD11b and CD11c mAb. Surface 
marker expression was analyzed 24 hrs after activation with (black lines) or without (grey) the 
respective stimulus. The diagram shows viable CD11b and CD11c positive cells and illustrates one 
representative experiment out of five. 
 
 
Figure 10: IL-12 secretion by HSC-derived DCs and splenic DC subsets. 
0.25 x 106 day 6 CD11c+ HSC-derived DCs/ml were activated with the indicated stimuli in 
combination with IFN-γ (A) and 0.5 x 106 splenic DC subsets/ml were activated with IFN-γ 
alone (B). Accumulated IL-12p70 levels in the supernatants were measured by ELISA 
assay 24 hrs later and compared to DCs cultured in medium alone (-). The values 
represent mean±SD of three experiments. 
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detected in immature CD11c+ HSC-derived DCs (Figure 10A). Upon activation with 
R848/IFN-γ, PolyIC/IFN-γ or J558L/IFN-γ, concentrations of 2.3±0.9 ng/ml, 1.4±0.7 
ng/ml or 2.4±2.3 ng/ml IL-12p70 were detected, respectively. More IL-12p70 was 
secreted in CD11c+ HSC-derived DC cultures stimulated with CD40 mAb/IFN-γ 
(4.7±0.9 ng/ml). The treatment with LPS/IFN-γ induced highest secretion of IL-12p70 
(5.8±1.9 ng/ml). 
Without additional stimulation, CD8- (0.4±0.2 ng/ml) and CD8+ (1.0±0.1 ng/ml) 
splenic DCs secreted basal IL-12p70 levels (Figure 10B). IFN-γ stimulation enhanced 
IL-12p70 production by CD8- splenic DCs (1.3±1.0 ng/ml) and CD8+ splenic DCs 
(2.4±1.0 ng/ml). IL-12p70 production tended to be superior in CD8+ splenic DCs 
when compared to CD8- splenic DCs. 
 
 
 
 
 
 
 
 
 
 
 
We investigated whether a reduced stimulation time period would still be sufficient to 
induce IL-12p70 secretion by CD11c+ HSC-derived DCs and analyzed the 
supernatants after 3 hrs LPS/IFN-γ stimulation and subsequent re-cultivation in 
medium alone for additional 21 hrs (Figure 11). As shown previously, immature 
CD11c+ HSC-derived DCs did not secrete IL-12p70. Activation with LPS/IFN-γ for 3 
hrs slightly reduced IL-12p70 concentrations (2.9±0.9 ng/ml) in comparison to 24 hrs 
stimulated CD11c+ HSC-derived DCs (6.5±1.8 ng/ml), suggesting that similarly to the 
human system a short stimulation is sufficient for IL-12 induction. 
  
 
Figure 11: IL-12 secretion by 3 hrs activated HSC-derived DCs. 
0.25 x 106 day 6 CD11c+ HSC-derived DCs/ml were activated with 
LPS/IFN-γ for 24 hrs (24 hrs) or for 3 hrs with subsequent re-culture in 
stimulus-free medium for additional 21 hrs (3 hrs). Accumulated IL-
12p70 levels in the supernatants were measured by ELISA assay and 
compared to DCs cultured in medium without activation stimulus (-). 
The values represent mean±SD of three. 
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IDO expression and activity in activated HSC‐derived and splenic DCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immature CD11c+ HSC-derived DCs did not express IDO at levels detectable by 
standard RT-PCR methods (Figure 12A). Upon activation, IDO-gene transcription 
was observed. IDO mRNA in CD8+ and CD8- splenic DCs was constitutive 
expressed and enhanced by IFN-γ treatment (Figure 12B). 
Levels of TRP and Kyn in the supernatant of DC cultures were examined by high 
performance liquid chromatography (HPLC, in generous collaboration with D. Fuchs) 
to detect constitutive or induced IDO activity, whereas lack of TRP depletion and Kyn 
accumulation indicate no enzymatic activity.  
Although IDO mRNA expression was detectable upon activation of CD11c+ HSC-
derived DCs and constitutively in splenic DCs, TRP and Kyn levels in the 
supernatants of CD11c+ HSC-derived DCs (Figure 13A) and splenic DCs (Figure 
13B) were similar to concentrations in medium alone (Figure 13C). Even one week 
after cultivation of HSC-derived and splenic DCs, IDO activity was lacking (data not 
shown). Interestingly, IDO activity in human monocyte derived DCs activated with 
 
 
Figure 12: IDO mRNA expression of HSC-derived and splenic DCs. 
0.25 x 106 day 6 CD11c+ HSC-derived DCs/ml were activated with the indicated stimuli 
in combination with IFN-γ (A) and 0.5 x 106 splenic DC subsets/ml were activated with 
IFN-γ alone (B) for 24 hrs. Expression of IDO mRNA by these cells and by cells cultured 
in medium alone (-) was analyzed by RT-PCR. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) cDNA levels were used to control equal gel loading. The 
diagram illustrates one representative experiment out of three. 
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LPS and IFN-γ could be routinely detected (Figure 13C), indicating a potential 
difference in the regulation of IDO activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: IDO activity in DC subtypes. 
0.25 x 106 day 6 CD11c+ HSC-derived DCs (A) or 0.5 x 106 splenic DC subsets (B)/ml medium 
were treated as described in Figure 12. TRP and Kyn levels in the supernatants were determined 
by HPLC analysis. Lack of TRP depletion and Kyn accumulation indicate no enzymatic activity. 
The values represent mean±SD of three experiments. I acknoledge B. Jürgens for providing data 
on human DCs. 
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Inactive IDO over­expressed in HSC­derived DCs 
In contrast to the literature, activation of HSC-derived DCs or CD8+ or CD8- splenic 
DC subsets did not induce IDO activity. Therefore, it was of substantial interest 
whether lack of IDO activity was caused by low IDO protein quantity. For this reason, 
we compared different transfection methods for HSC-derived DCs to subsequently 
use the most optimal one to over-express IDO. 
 
Comparison of transfection methods for HSC­derived DCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Surface marker expression by transfected HSC-derived DCs. 
HSC-derived DCs were double stained with isotype-matched mAb (A) or with anti-CD11c in 
addition to CD11b, CD80, CD86 or MHC class II mAb (B). Marker expression was analyzed 24 
hrs (lipofection, lentivirus, electroporation) or 6 days after transfection (retrovirus) and compared 
to un-transfected cells. The diagram shows viable cells and illustrates one representative 
experiment out of three. 
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HSCs during DC generation or day 6 HSC-derived DCs with or without enrichment 
according to the expression of CD11c were transfected with the indicated method 
using compatible green fluorescence protein- (GFP-) encoding vectors. Cells were 
tested by flow cytometry regarding GFP expression, representing transfection 
efficiency, possibly altered cell viability and unwanted induction of activity by the 
particular method in comparison to DCs left un-transfected 24 hrs later. The different 
transfection methods used are described in detail in materials and methods. 
 
 
 
 
 
 
 
 
 
Lipofectamine transfection of HSC‐derived DCs 
To examine the transfection efficiency of lipofectamine in HSC-derived DCs, cells 
were transfected with pMax-GFP at different time points of DC generation and 
analyzed 24 hrs post transfection. 
Transfection of day 6 HSC-derived DCs with lipofectamine did not up-regulate CD80, 
CD86 and MHC class II expression 24 hrs after manipulation (Figure 14B, 2nd row) in 
comparison to un-transfected day 7 CD11c+ DCs (Figure 14B, 1st row). To evaluate 
whether transfection of precursor cells or DCs was more effective, cells were 
additionally transfected on day 1, 4 and 5 of DC generation. GFP expression was 
never detected 24 hrs later (Figure 15, 2nd dot plot and Figure 16A). 7AAD, a nucleic 
acid dye that stains dead cells, was used to determine cell viability. However, 
transfection with lipofectamine did not substantially reduce the viability of the cells 
(Figure 16A). 
 
 
Figure 15: GFP expression by transfected HSC-derived DCs. 
GFP transfected or un-transfected HSC-derived DCs were stained with anti-CD11c mAb. The 
percentage of CD11c and GFP co-expressing cells was determined either 24 hrs (lipofection, 
lentivirus, electroporation) or 6 days post transfection (retrovirus). The diagram shows viable 
cells and illustrates one representative experiment out of three. 
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The method and the reagent itself were efficient for transfection strategies in cells 
other than DCs. When HeLa cells were transfected with lipofectamine, 68% of the 
cells were positive for GFP expression after 24 hrs (Figure 16B), whereas un-
transfected HeLa cells never expressed GFP. HSC-derived DCs were not able to 
express GFP; transfection with lipofectamine was concluded not to be suitable for 
DCs. 
 
 
 
 
 
 
 
 
 
 
Lentivirus transfected HSC‐derived DCs 
Next, the efficiency of lentiviral transfection of HSC-derived DCs was evaluated. The 
generated lentiviral particles were titered as described in materials and methods and 
subsequently used to transfect day 6 HSC-derived DC populations at a multiplicity of 
infection of one. 
Expression of CD80, CD86, MHC class II (Figure 14, 3rd row), and viability (data not 
shown) was not altered 24 hrs post lentiviral transfection when compared to un-
transfected DCs (Figure 14, 1st row). CD11c negative cells could be detected as 
HSC-derived DCs were not CD11c MACS enriched. Although lentivirally transfected 
HSC-derived DCs lacked an altered DC phenotype and decreased viability, only 16% 
of the cells expressed GFP (Figure 15, 3rd dot plot), which excluded this method for 
further experiments.  
 
 
 
Figure 16: HSC-derived DCs and HeLa cell transfection with lipofectamine. 
HSC-derived DCs were stained with anti-CD11c mAb and 7-AAD. GFP 
expression and viability of CD11c+ DCs was analyzed by flow cytometry 24 hrs 
after transfection with lipofectamine at different time points of DC generation 
(A). HeLa cells were stained with 7-AAD (B). GFP expression of lipofectamine 
transfected cells (HeLa-GFP) was analyzed by flow cytometry and compared to 
untreated cells (HeLa). The diagram shows 7-AAD negative populations 
representing viable cells and illustrates one representative experiment out of 
three. 
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Retroviral transfection of HSCs and differentiation into HSC‐derived DCs 
Further, the efficiency of retroviral transfection of dividing HSCs was investigated. For 
the production of GFP-encoding retroviral particles, ecotropic packaging Phoenix 
cells were transfected with MSCV-MigR1-GFP using lipofectamine. 24 hrs later cells 
were irradiated. Another 24 hrs later, the un-transfected and GFP-transfected 
Phoenix cells were analyzed for the expression of GFP by flow cytometry and 
subsequently used for co-culture experiments with freshly isolated HSCs. After two 
days of co-culture, HSCs were recovered and re-cultured alone for additional four 
days. Further testing was done, but without sorting according to CD11c expression. 
97% and 86% of un-transfected and GFP-transfected Phoenix cells, respectively, 
were viable (data not shown) and 68% of the transfected cells were GFP positive 
(Figure 17). 
 
 
 
 
 
 
 
 
 
 
 
The presence of retrovirus producing Phoenix cells did no influence the generation of 
HSC-derived DCs (Figure 14, 4th row). The percentage of CD11b/c positive DCs and 
the expression density of CD80, CD86 and MCHII were comparable to that of DCs 
generated under control conditions (Figure 14, 1st row). GFP expressing cells were 
also positive for CD11c, the most prominent DC marker (Figure 15, 4th dot plot). 
However, GFP expression was not observed when co-cultures were conducted with 
un-transfected Phoenix cells. Usually, DC cultures were more than 90% viable. 
 
 
Figure 17: Phoenix cell transfection with lipofectamine. 
GFP expression was analyzed 24 hrs after lipofectamine 
transfection (Phoenix-GFP) and compared to cells without 
treatment (Phoenix). The diagram shows viable cells and 
illustrates one representative experiment out of three. 
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Phoenix cells did not express CD11b and CD11c thus demonstrating that GFP 
expressing cells were solely of DC origin (data not shown). Our experiments provide 
evidence that HSC can be transfected by retroviral particles to some extent and that 
further differentiation into DCs is not altered. 
 
Transfection of HSC‐derived DCs by electroporation technique 
The final transfection method evaluated was the electroporation technique (Dullaers, 
Breckpot et al. 2004). Day 6 CD11c+ HSC-derived DCs were either left un-
transfected, or transfected with pMax-GFP vector and analyzed 3 to 72 hrs later. 
 
 
 
 
 
 
 
 
 
In comparison to un-transfected DCs (Figure 14, 1st row), GFP transfected DCs 
showed slight up-regulation of DC surface markers (Figure 14, 5th row) and minimal 
reduction of cell viability from 96% to 86% (data not shown). GFP expression by DCs 
was tested at various time points after manipulation. While un-transfected DCs never 
showed GFP expression (data not shown) more than 50% of the GFP transfected 
cells were tested positive after 24 hrs (Figure 15, 5th dot plot). Already 3 hrs and up to 
72 hrs after treatment, GFP expression was detectable (Figure 18). Transfection of 
24 hrs LPS/IFN-γ stimulated DCs did not increase the percentage of GFP positive 
DCs (data not shown). Electroporation emerged as the most efficient method to 
transfect CD11c+ HSC-derived DCs and was subsequently used for all experiments. 
 
 
 
Figure 18: Transfection of HSC-derived DCs by 
electroporation technique. 
Day 6 CD11c+ HSC-derived DCs were stained with anti-CD11c 
mAb. The percentage of GFP expressing CD11c+ cells was 
analyzed up to 72 hrs after transfection. Diagram shows viable 
CD11c+ cells. 
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Over­expression of IDO 
IDO transfected mammalian cell lines 
To evaluate whether IDO produced by IDO transfected cells is active, different 
mammalian cell lines were transfected by electroporation technique. Several murine 
and human cell lines were either transfected with pMax-GFP (GFP), co-transfected 
with pMax-IDO and pMax-GFP (IDO/GFP) or left un-transfected. 24 to 72 hrs later, 
cells were tested for viability and GFP expression by flow cytometry. In addition, IDO 
mRNA expression and activity were determined by RT-PCR and HPLC analysis, 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We found GFP expression in all cell lines which were transfected with GFP 24 hrs 
later (Figure 19A). While approximately 50% of the murine J558 and the human 
Phoenix cells were GFP positive, up to 80% of the murine Raw264.7 and human 
 
 
Figure 19: IDO expression by murine and human cell lines. 
0.25 x 106 cells/ml medium were either transfected with pMax-GFP (GFP), co-transfected with 
pMax-IDO and pMax-GFP (IDO/GFP) by electroporation technique or left un-transfected (-). GFP 
expression was analyzed by flow cytometry 24 hrs later. Dot plots show viable cells (A). The 
expression of IDO-specific mRNA by the different cell types was analyzed by RT-PCR up to 72 
hrs later. GAPDH cDNA levels were used to control equal gel loading (B). Cells were stained with 
7-AAD and analyzed by flow cytometry to evaluate viability up to 72 hrs later (C). 
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HeLa cells expressed GFP. Un-transfected cells never expressed GFP. IDO/GFP co-
transfection did not alter the percentage of GFP positive cells. IDO mRNA expression 
was solely detected in co-transfected cells; irrespective of the time point tested 
(Figure 19B). Staining with 7AAD to determine viable cells showed that viability was 
not affected by electroporation treatment 24 to 72 hrs later (Figure 19C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supernatants of these cell cultures were tested for IDO activity 24 to 72 hrs after 
treatment (Figure 20). Exclusively co-transfected cell lines showed TRP depletion 
and Kyn accumulation. Whereas murine J558 cells depleted TRP and accumulated 
Kyn to a minor extent, complete TRP depletion and massive Kyn accumulation was 
detected in the other cell lines 72 hrs after treatment. We suggest that TRP depletion 
without accumulation of Kyn in un-transfected and GFP transfected cell lines was 
most probably due to nutrient consumption, caused by rapid cell growth. 
Electroporation was shown to be an efficient method to transfect a variety of murine 
and human cell lines. IDO/GFP co-transfection resulted in active IDO expression, 
indicating that the artificially over-expressed IDO was able to work as the naturally 
described enzyme.  
 
 
Figure 20: IDO activity in murine and human cell lines. 
0.25 x 106 cells/ml medium were treated as described in Figure 19. TRP (full symbols) and Kyn 
(empty symbols) levels in the supernatants were determined by HPLC analysis up to 72 hrs later. 
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IDO transfected HSC‐derived DCs 
To investigate the effect of over-expressed IDO in HSC-derived DCs, cells were 
transfected with an IDO-encoding vector using the electroporation technique. Day 7 
CD11c+ HSC-derived DCs were either transfected with pMax-GFP (GFP), co-
transfected with pMax-IDO and pMax-GFP (IDO/GFP) or left un-transfected. 
Subsequently, these cells were cultured with and without LPS/IFN-γ for 3 hrs and re-
cultured in fresh medium for additional 21 hrs. To verify that DC activation and 
cytokine secretion was independent of electroporation treatment, cells were analyzed 
for the expression of DC surface markers and viability by flow cytometry, and IL-
12p70 secretion by ELISA assay. The same cells were consecutively tested for the 
expression of IDO mRNA by RT-PCR, of IDO protein by western blot and for IDO 
activity by HPLC analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Flow cytometry was done using activated DCs with (LPS/IFN-γ activated DCs-
IDO/GFP) and without IDO/GFP co-transfection (LPS/IFN-γ activated DCs) in 
comparison to DCs left immature (immature DCs). DCs typically consisted of two cell 
populations expressing DC surface markers CD80, 86 and MHC class II at a low or 
 
 
Figure 21: Surface marker expression by transfected and activated HSC-derived DCs. 
DCs were tripled stained with either isotype-control mAb (A) or anti-CD80, CD86 or MHC class II 
mAb in addition to anti-CD11b and CD11c mAb (B). Day 7 CD11c+ HSC-derived DCs were co-
transfected with pMax-IDO and pMax-GFP by electroporation technique, activated with LPS/IFN-γ for 
3 hrs and subsequently re-cultured in medium alone (LPS/IFN-γ activated DCs-IDO/GFP). Marker 
(B) and GFP expression (C) was analyzed by flow cytometry 24 hrs later and compared to un-
transfected DCs with (LPS/IFN-γ activated DCs) or without (immature DCs) equal activation. The 
diagram shows viable cells and illustrates one representative experiment out of three. 
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high expression density (Figure 21B). Most activated DCs, independent of the 
electroporation treatment, expressed the markers to a higher level, whereas most of 
the immature DCs expressed these markers at a lower level. GFP expression was 
solely observed in co-transfected DCs with intensity equal to earlier experiments 
where DCs were transfected with GFP only (Figure 21C and Figure 15). Cell viability 
was minimally decreased from 92% to 88% upon activation and to 74% upon 
additional co-transfected (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
IL-12p70 was solely detected in supernatants of activated DCs, independent of 
electroporation treatment (Figure 22). Un-transfected, GFP transfected and IDO/GFP 
co-transfected DCs produced 2.9±0.9 ng/ml, 3.9±1.5 ng/ml, and 3.8±1.9 ng/ml, 
respectively. DCs without activation stimulus never secreted IL-12p70. 
In un-transfected and GFP transfected DCs, IDO mRNA expression was induced 
upon activation (Figure 23A). Usually, the expression of IDO mRNA in IDO/GFP co-
transfected DCs was most prominent and irrespective of cell activation. IDO protein 
expression was usually detectable in all DC cultures, independent of stimulation or 
electroporation treatment (Figure 23B). Activation of un-transfected and GFP 
transfected DCs provoked increased IDO protein expression in comparison to 
immature cells. IDO protein expression by IDO/GFP co-transfected DCs was always 
superior to the other DCs, independent of cell activation. 
 
 
Figure 22: IL-12 secretion by transfected and activated HSC-derived DCs. 
0.25 x 106 day 7 CD11c+ HSC-derived DCs/ml were either transfected with pMax-
GFP (GFP), co-transfected with pMax-IDO and pMax-GFP (IDO/GFP) by 
electroporation techique or left un-transfected (-). Subsequently, these cells were 
cultured with and without LPS/IFN-γ for 3 hrs and re-cultured in fresh medium for 
additional 21 hrs. Accumulated IL-12p70 levels in the supernatants were measured 
by ELISA assay. The values represent mean±SD of three experiments.  
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Supernatants of the above tested DC cultures were tested for IDO activity by HPLC 
analysis. As shown in previous experiments (Figure 13), un-transfected and GFP 
transfected DCs, irrespective of their activation status, did not express active IDO 
(Figure 24). Surprisingly, IDO over-expressing DCs, with and without activation 
stimuli, were also negative for IDO activity, as TRP and Kyn levels in the cultures 
were comparable to medium alone (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: IDO mRNA/protein expression by transfected and activated HSC-derived DCs. 
0.25 x 106 day 7 CD11c+ HSC-derived DCs/ml medium were treated as described in Figure 22. 
Expression of IDO- mRNA (A) and proteins (B) was analyzed by RT-PCR and western blotting, 
respectively. GAPDH cDNA and protein levels were used to control gel loading. The diagram 
illustrates one representative experiment out of three. 
 
 
Figure 24: IDO activity in transfected and activated HSC-derived DCs. 
0.25 x 106 day 7 CD11c+ HSC-derived DCs/ml medium were treated as described in 
Figure 22. TRP and Kyn levels in the supernatants were determined by HPLC 
analysis. The values represent mean±SD of three experiments.  
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IDO  transfected  HSC­derived  DCs  stimulate  T  cell 
proliferation in vitro 
Reports suggested that IDO activation in DCs could be induced by certain signals, 
normally mediated by T cells (Hwu, Du et al. 2000; Mellor, Baban et al. 2003). We 
questioned whether DCs, co-cultured with T cells, induce IDO activity. Day 7 CD11c+ 
HSC-derived DCs were either transfected with pMax-GFP (GFP), co-transfected with 
pMax-IDO and pMax-GFP (IDO/GFP), or left un-transfected. After subsequent 
stimulation with LPS/IFN-γ and loading with OVA-peptide or SIINFEKL for 3 hrs, cells 
were co-cultured with 5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester 
(5(6)-CFDA (CFSE) mixed isomers labeled TCR transgenic OT2 (CD4) or OT1 (CD8) 
T cells, respectively. Co-cultures were conducted in ratios from 1:1 to 1:105 DCs to T 
cells. After three days the percentage and total number of proliferating T cells were 
analyzed by flow cytometry. Additionally, supernatants were analyzed for enzyme 
activity by HPLC analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
Typically, 85% CD4 positive and 90% CD8 positive T cells were obtained with MACS 
enrichment procedures (Figure 25). 
 
 
Figure 25: CD4 and CD8 T cell purification. 
CD4 and CD8 T cell purification from OT2 and OT1 C57BL/6 mice respectively, 
was evaluated by flow cytometry analysis. Total spleen cells and the positive (CD4+ 
and CD8+) and negative (CD4- and CD8-) MACS sorted cell fractions were stained 
with anti-CD4 or CD8 mAb in addition to anti-CD3 mAb. The diagram shows 
analysis of  viable cells and illustrates one representative experiment out of three.  
Results    
49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Figure 26A and B, the percentage of proliferated CD4 and CD8 T cells in co-
culture settings was analyzed, respectively. The low or un-existing proliferation in 
cultures with CD4 or CD8 T cells alone (negative control) could be enhanced to 60% 
or 88%, respectively, upon stimulation with αCD3 mAb (positive control). CD4 T cells 
proliferated optimal in co-culture with 104 and 103 DCs. 105, 104 and 103 DCs were 
optimal to induce proliferation of CD8 T cells. We found a general decreased T cell 
proliferation with reduced DC numbers. Irrespective of IDO over-expression by DCs, 
the percentage of proliferating CD4 or CD8 T cells was akin. 
TruCount technique enabled the determination of total numbers of proliferated CD4 
and CD8 T cells as shown in Figure 26C and D, respectively. However, no significant 
difference in the total number of proliferated CD4 or CD8 T cells was measured, 
irrespective of the over-expressed IDO protein by DCs. 
 
 
Figure 26: Percentages and total numbers of proliferated CD4 or CD8 T cell. 
Day 7 CD11c+ HSC-derived DCs were either transfected with pMax-GFP (GFP), co-transfected 
with pMax-IDO and pMax-GFP (IDO/GFP) or left un-transfected (-). Subsequently, cells were 
activated with LPS/IFN-γ and loaded with10 µg/ml OVA-peptide for co-cultures with OT2 T cells 
(A and C) or with 10 ng/ml SIINFEKL for co-cultures with OT1 T cells (B and D) for 3 hrs. Cells 
were co-cultured with CFSE labeled T cells at indicated ratios. Control T cells were cultured 
alone (negative control) or in presence of 1 µg/ml αCD3 mAb (positive control). After 3 days cells 
were stained with anti-CD4 or anti-CD8 mAb and analyzed by flow cytometry. The diagram 
shows the percentage (A and B) and the total number (C and D) of proliferated T cells. 
Proliferated T cells were defined by their loss of green fluorescence due to CFSE dilution 
compared to maximum green fluorescence in un-proliferated T cells. The values represent 
mean±SD of three experiments. 
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Supernatants of the above described co-cultures were tested for IDO activity by 
HPLC analysis. Analyses showed that co-culture of DCs with CD4 (Figure 27A), as 
well as with CD8 (Figure 27B) T cells did not induce IDO activity, irrespective of 
whether IDO was over-expressed or not. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: IDO activity in HSC-derived DC co-cultures with CD4 or CD8 T cells. 
The supernatants of co-cultures described in Figure 26 with either OT2 (CD4) (A and C) or OT1 
(CD8) (B and D) T cells, respectively, were tested for TRP depletion (full symbols) and Kyn 
accumulation (empty symbols) by HPLC analysis. The values represent mean±SD of three 
experiments. DC-IDO/GFP, pMax-IDO and pMax-GFP co-transfected DCs; DC-GFP, pMax-GFP 
transfected DCs; DC, un-transfected DCs. 
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Enhanced NO production in activated HSC­derived DCs 
To investigate, whether NO production inhibits IDO activity (Wood and Sawitzki 
2006), we tested supernatants of HSC-derived DC, cultured alone, or in co-cultures 
with CD4 or CD8 T cells at ratios of 1:1 for accumulated NO. Levels of NO were 
examined by Griess reaction in generous collaboration with D. Fuchs. 
 
 
 
 
 
 
 
 
 
 
 
Un-transfected, GFP transfected, and IDO/GFP co-transfected DCs without further 
stimulation produced 13.1±4.9 µmol/L, 14.0±17.1 µmol/L and 9.2±3.5 µmol/L NO, 
respectively (Figure 28). Activation with LPS/IFN-γ usually enhanced NO production. 
After activation, un-transfected DCs produced 44.6±17.9 µmol/L, GFP transfected 
produced 54.6±21.2 µmol/L and IDO/GFP co-transfected produced 43.3±5.6 µmol/L 
NO. Enhancement of NO after activation with LPS/IFN-γ was significant for un-
transfected and IDO/GFP co-transfected DCs. GFP transfected DCs had an un-
significant tendency for enhanced NO production. 
Supernatants of co-cultures additionally provided evidence for the presence iNOS 
activity (Figure 29). Un-transfected, GFP transfected and IDO/GFP co- transfected 
DCs produced 38.8±0.2 µmol/L, 23.2±2.1 µmol/L and 19.6±2.9 µmol/L NO in co-
cultures with CD4 T cells, respectively, or 55.3±0.8 µmo/L, 18.6±7.2 µmol/L and 
17.4±9.3 µmol/L NO in co-cultures with CD8 T cells, respectively. T cells cultured 
 
 
Figure 28: iNOS activity in HSC-derived DCs. 
0.25 x 106 day 7 CD11c+ HSC-derived DCs/ml medium were treated as described in Figure 22. 
To determine iNOS activity, NO levels in the supernatants were measured. The values represent 
mean±SD of three experiments. -, un-transfected; GFP, pMax-GFP transfected DCs; IDO/GFP, 
pMax-IDO and pMax-GFP co-transfected DCs. 
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alone, even after stimulation with αCD3 mAb did not show any iNOS activity, thus 
confirming that iNOS is solely active in DCs (data not shown). 
 
 
 
 
 
 
 
 
 
 
Supernatants of IDO/GFP co-transfected murine and human cell lines that expressed 
active IDO were tested negative for iNOS activity (Figure 30). J558 cells produced 
0.7±0.5 µmol/L, Raw 264.7 cells 2.7±1.8 µmol/L, Phoenix cells 1.8±0.5 µmol/L and 
HeLa cells 0.1±0.0 µmol/L NO. These experiments provide evidence that iNOS 
activity is possibly involved in the inhibition of IDO activity. Usually, iNOS activity was 
solely found in cultures (mainly HSC-derived DCs) that expressed inactive IDO, but 
not in those (murine and human cell lines) that expressed active IDO.  
 
 
 
 
 
 
 
 
 
 
 
Figure 29: iNOS activity in HSC-derived DC co-cultured with CD4 or CD8 T cells. 
The supernatants of co-cultures described in Figure 26 of 1:1 ratios with either OT2 (CD4) (A and 
C) or OT1 (CD8) (B and D) T cells respectively, were tested for NO accumulation. The values 
represent mean±SD of three experiments. -, un-transfected DCs; GFP, pMax-GFP transfected 
DCs; IDO/GFP, pMax-GFP and pMax-IDO co-transfected DCs. 
 
 
Figure 30: iNOS activity in IDO/GFP co-transfected murine and human cell lines. 
0.25 x 106 cells/ml medium were co-transfected with pMax-GFP and pMax-IDO. To 
determine iNOS activity, NO levels in the supernatants were measured. The values 
represent mean±SD of three experiments. 
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Discussion 
Anti-tumor DC vaccines for cancer immunotherapy are intensively tested for their 
potential to support conventional chemotherapy (Banchereau and Palucka 2005; Zou 
2005; Steinman and Banchereau 2007). However, their modest success might be 
explained by the increased resistance of malignant cells to immune attacks. 
Malignant cells may acquire resistance during cancer immunoediting through several 
tolerogenic mechanisms (Dunn, Bruce et al. 2002; Zhou, Drake et al. 2006). Among 
them, expression of active IDO by DCs has recently been identified as a potential 
impediment for successful cancer immunotherapy (Munn and Mellor 2004; Munn and 
Mellor 2007). We hypothesize that a down-regulation of IDO in DCs used as anti-
tumor vaccines may increase their power in promoting tumor immunity (Muller, 
DuHadaway et al. 2005; Hou, Muller et al. 2007).  
 
The functionality of DCs used in an anti-tumor DC vaccine trial conducted by our 
group was previously substantiated in prophylactic and therapeutic tumor mouse 
models (Huttner, Breuer et al. 2005). In this study it was shown that prophylactic 
immunization with activated HSC-derived DCs of BALB/c mice mediated complete or 
partial protection of tumor development, depending on the antigen used. Therapeutic 
immunization with activated HSC-derived DCs of this inbred strain was successful 
within 12 days after tumor cell challenge. In the current study we used HSC-derived 
DCs from C57BL/6 mice, because this allowed us to study any T cell inhibition in the 
syngeneic OT1 and OT2 system. The main purpose was to analyze whether the T 
cell stimulatory capacity of activated HSC-derived DCs of C57BL/6 is potentially 
impeded by expression of enzymatically active IDO in vitro. 
 
While IDO mRNA and protein expression was readily detectable in various types of 
activated murine DCs, enzymatic activity was never detected. The causes for this 
observation may be manifold. We performed the following attempts to explore 
mechanisms that may prevent the onset of IDO enzymatic activity in the murine 
system, (i) insufficient DC activation, (ii) unsuitable mouse strain, (iii) insufficient IDO 
expression, (iv) insufficient IDO protein quantity or (v) inhibition by iNOS activity. 
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(i) Studies have shown that different types of DCs that constitutively express IDO 
protein need to be sufficiently activated by certain stimuli to express enzymatically 
active IDO (Fallarino, Vacca et al. 2002; Grohmann, Orabona et al. 2002; Fallarino, 
Grohmann et al. 2003). We assume that inactive IDO in our DC cultures is due to 
insufficient DC activation. In previous studies we were able to show that sufficiently 
activated human and murine DCs are characterized by up-regulation of cell surface 
markers such as MHC class II (Signal 1), CD80 and CD86 (Signal 2), as well as by 
secretion of Th1 polarizing cytokine IL-12 (Signal 3). The concerted activation of all 
three signals was shown to be important to allow generation of CTL that trigger 
effective anti-tumor immunity (Felzmann, Huttner et al. 2005; Huttner, Breuer et al. 
2005). We also found up-regulation of DC surface markers and secretion of IL-12 in 
activated HSC-derived, as well as in CD8+ and CD8- splenic DC-cultures. We 
conclude that insufficient activation of the different investigated types of DCs can be 
neglected as a reason for inactive IDO.  
(ii) Studies have shown that genetic variances of different inbred strains of mice 
determine, among others, the outcome of certain infections, e.g. susceptibility to 
induced colitis (Mahler, Bristol et al. 1998; Houpt, Glembocki et al. 2002; Suzuki, 
Kohno et al. 2006). We asked whether the genetic background of C57BL/6 mice, 
which were exclusively used in our study, is appropriate to induce enzymatic activity 
in IDO protein. The original observation of IDO enzymatic activity to prevent fetus 
rejection in allogeneic pregnancies by suppressing T cell responses was found in 
CBA/CaJ mice (Munn, Zhou et al. 1998; Mellor and Munn 2004). IDO activity in DCs 
enriched from different organs that were activated in vitro was mostly found in mouse 
strains other than C57BL/6 mice, e.g. DBA/2J mice for investigating IDO activity in 
CD8+ and CD8- splenic DCs (Fallarino, Vacca et al. 2002; Belladonna, Grohmann et 
al. 2006). However, basal and induced IDO enzymatic activity was also found in 
splenic DCs from C57BL/6 mice (Grohmann, Orabona et al. 2002; Orabona, 
Tomasello et al. 2005). Mostly, C57BL/6 mice were used to investigate IDO activity in 
DCs enriched from different organs after in vivo manipulation. In these studies, IDO 
activity was found after implantation of tumor cells (Munn, Sharma et al. 2004), 
elicitation of local inflammation (Muller, Sharma et al. 2008), exposure to CpG 
oligodeoxynucleotides (Mellor, Baban et al. 2005), or exposure to CLTA-4-Ig 
(Grohmann, Orabona et al. 2002). Little evidence exists that HSC-derived DCs of 
C57BL/6 mice are also competent to express enzymatically active IDO (Lee, Jeong 
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et al. 2007). Subsuming, IDO activity has been demonstrated in various mouse 
strains. Among them C57BL/6 mice have been used in some of the crucial studies 
delineating mechanisms of IDO activity. We conclude that C57BL/6 mice are suitable 
to investigate IDO enzymatic activity in HSC-derived DCs. 
(iii) We previously determined sufficient DC activation, featuring one of the factors 
crucial for IDO enzymatic activity. In addition, sufficient induction or else 
augmentation of IDO mRNA and protein expression are essential. Studies have 
shown that in HSC-derived DCs IDO expression needs to be induced (Jung, Lee et 
al. 2007; Hara, Ogasawara et al. 2008), whereas CD8+ and CD8- splenic DCs 
constitutively express IDO (Fallarino, Vacca et al. 2002). As expected, we found IDO 
mRNA and protein expression in HSC-derived DCs after activation with different 
stimuli (LPS, R848, PolyIC or CD40 cross-linking) in combination with IFN-γ. CD8+ as 
well as CD8- splenic DCs constitutively expressed IDO mRNA, which could be 
amplified after treatment with IFN-γ. 
(iv) Although IDO expression was induced or else enhanced in our DC cultures, it 
remains unclear whether this level of transcription is sufficient to produce adequate 
amounts of IDO protein. Attenuated IDO protein expression might lead to enzymatic 
activity below detection limit. We co- transfected HSC-derived DCs with an IDO- and 
GFP-encoding vector using electroporation technique and induced GFP expression 
in more than 50% of DCs 24 hours after treatment. In the same cells we also found 
significant over-expression of IDO protein. However, even with this abundant protein 
expression, no evidence for IDO enzymatic activity was found. We conclude that lack 
of IDO activity is most likely not due to low protein quantities.  
(v) In the mammalian system IDO is a highly conserved protein. However, while IDO 
activity in human monocyte derived DCs activated with LPS and IFN-γ could be 
routinely detected (Jurgens, Hainz et al. 2009), we never detected IDO enzymatic 
activity in murine DCs from C57BL/6 mice. Several studies provide evidence that 
immunological differences are not the exception within human and murine organisms 
(Mestas and Hughes 2004). While a potential difference in regulating IDO activity still 
remains unclear, differences in the regulation of iNOS activity associated with the 
inhibition of IDO activity was shown (Thomas, Mohr et al. 1994). Additional studies 
provide evidence that stimulated HSC-derived DCs express inactive IDO due to 
simultaneous induction of iNOS (Hara, Ogasawara et al. 2008). In our study, levels of 
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NO in HSC-derived DCs that expressed inactive IDO were constitutively present and 
enhanced after treatment with LPS and IFN-γ. Interestingly, IDO transgenic human 
(Phoenix and HeLa) and murine cell lines (Raw264.7 and J558) that express active 
IDO lack iNOS activity. These results might provide evidence for the influence of 
functional iNOS on the onset of IDO enzymatic activity.  
 
In a single report it has been suggested that HSC-derived DCs of C57BL/6 express 
enzymatically active IDO after treatment with LPS and IFN-γ. In addition, these cells 
were associated with IDO-dependent suppression of syngeneic OT1 T cell 
proliferation in vitro (Lee, Jeong et al. 2007). The key characteristics of these murine 
HSC-derived, active IDO expressing DCs, are described by nonadherence and 
expression of CD11c. In our study, DCs which were characterized by the same origin 
and phenotype never expressed enzymatically active IDO. Moreover, in our co-
cultures with OT1 or OT2 T cells, vigorous T cell responses were induced which were 
proportional to the number of OVA-peptide pulsed and LPS and IFN-γ activated 
HSC-derived DCs. We further suggest that these DCs mediate a pro-inflammatory 
effect on a per cell basis. 
Two parameters are used to determine IDO activity: the reduction of TRP and the 
augmentation of Kyn concentration. In our study, we measured TRP and Kyn 
concentrations in cell culture supernatants by HPLC technique, a widespread method 
to investigate IDO activity. With this technique we can directly draw conclusion from 
the extent of IDO activity in the cell cultures. In contrast to this method the group of 
Lee, Jeong et al. 2007 measured the Kyn formation of cellular extracts. Thereby, the 
cellular extracts are resuspended in an “IDO buffer”, including methylene blue and 
ascorbate that were previously described as redox factors for IDO activation in vitro 
(Takikawa 2005). Interestingly, a study using HSC-derived DCs from C57BL/6 mice 
showed that IDO activity could solely be detected by the enzyme assay as described 
in the study of Lee, Jeong et al. 2007. In contrast, no IDO activity could be detected 
in the supernatants of IDO expressing DC cultures by HPLC analysis directly (Hara, 
Ogasawara et al. 2008). However, the authors assume that iNOS activity has solely 
weak impact on the inhibition of IDO activity, as increased Kyn concentrations were 
far below those found in other studies (Grohmann, Orabona et al. 2002; Belladonna, 
Grohmann et al. 2006). 
Discussion    
57 
Whether HSC-derived DCs represent a suppressive subset of IDO-producing DCs is 
of pivotal importance for the regulation of immune responses, particularly for an 
improved design of anti-tumor DC vaccines. In the current study, we have shown that 
under experimental conditions used, nonadherent CD11c+ HSC-derived DCs neither 
express active IDO nor suppress syngeneic T cell response in vitro. It appears that 
the experimental conditions are favorable to generate a strong immuno-stimulatory 
phenotype in activated HSC-derived DCs. Regulation of IDO activity seems to involve 
a complex array of molecules that are still poorly understood. Our experiments 
suggest that iNOS activity may contribute to the inhibition of IDO activity in activated 
HSC-derived DCs, however, it may not be the only and not the most dominant factor. 
It would be of crucial importance to evaluate whether other inhibitory mechanisms 
counteract the otherwise potent T cell stimulatory capacity of HSC-derived DCs. 
In summary, our data suggest that apparently murine HSC-derived DCs maintain IDO 
in an enzymatically inactive form. IDO protein expression without enzymatic activity in 
murine HSC-derived DCs does obviously not interfere with their potent T cell 
stimulatory capacity in vitro. 
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Materials and Methods 
Cell culture 
Mice 
C57BL/6, OT-1 TCR transgenic (OVA257-264/H-2Kb–restricted) and OT-2 TCR 
transgenic (OVA323-339/I-Ab–restricted) mice were bred in the animal facility of the 
Institute of Pharmacology (Medical University of Vienna, Austria). All mice were 
maintained under specific pathogen-free conditions following a protocol approved by 
the Institutional Animal Care and Use Committee and in accordance with the ethical 
guidelines of the Federal Ministry of Science and Culture. All experiments were 
conducted with 6–8 week-old female mice. 
 
Media and cell lines 
The DC culture medium (subsequently termed normal cell culture medium, NCM) 
was RPMI 1640 supplemented with 2 mM L-glutamine, 100 µg/ml streptomycin, 100 
U/ml penicillin, 10 mM HEPES, 1 mM sodium pyruvate, 0.1 mM nonessential AA and 
50 µM 2-mercaptoethanol (all from Invitrogen, Grand Island, N.Y.). If not stated 
otherwise, NCM was supplemented with 10% (v/v) heat inactivated fetal calf serum 
(subsequently termed FCS; PAA Laboratories GmbH, Pasching, Austria). 
HeLa cells, a human carcinoma cell line, were cultured in RPMI 1640 supplemented 
with 2 mM L-glutamine and 10% FCS. 293FT cells, a primary embryonal human 
kidney cell line that stably expresses the SV40 large T antigen, were cultured in D-
MEM supplemented with 2 mM L-glutamine, 0.1 mM nonessential aminoacids, 1 
mMs sodium pyruvate, 10% FCS and 500 µg/ml geneticin (Invitrogen). Phoenix cells, 
a cell line based on the 293T cells, were cultured in D-MEM supplemented with 2 mM 
L-glutamine and 10% FCS. J558, a murine BALB/c myeloma cell line and J558L, a 
modified J558 cell line transfected with murine CD40L cDNA, were cultured in NCM 
without streptomycin and penicillin. Raw 264.7, a murine macrophage cell line, were 
cultured in D-MEM supplemented with 10% FCS.  
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Opti-MEM® I medium was used for transfection experiments with Lipofectamine™ 
2000 (both from Invitrogen).  
 
General incubation conditions and treatment of adherent cells 
Cells were cultured at 37°C in a humidified incubator containing 5% CO2. 
Centrifugation, if not stated otherwise, was done for 7 minutes at 400 g at 4°C. 
Adherent cell lines were detached using either Accutase (PAA Laboratories GmbH, 
Pasching, Austria) or 0.25% Trypsin-EDTA (Invitrogen). Briefly, after washing the 
adherent cells with 1х phosphate-buffered saline (PBS) (Invitrogen), the reagent was 
applied for 5 minutes at 37°C. Detached cells were collected, washed twice and re-
cultured in the respective medium. 
 
DC subtypes 
Generation of HSC‐derived DCs 
DCs were generated from mouse HSCs according to an established protocol (Inaba, 
Inaba et al. 1992; Lutz, Kukutsch et al. 1999) with minor modifications. Briefly, femurs 
and tibias of female C57BL/6 mice were dislodged and remaining tissue and muscles 
were removed with sterile gauze. The bones were sterilized with 70% (v/v) EtOH in a 
60-mm petri dish for 1 minute, air-dried and placed into NCM. Both ends of the bones 
were cut with sterile scissors, and then the bone marrow was flushed with 10 ml of 
NCM (Invitrogen, Carlsbad, USA) using a syringe and a 27G¾ needle (BD 
Microlances). The HSCs were centrifuged and the pellet resuspended in NCM. After 
counting, the cells were cultured in 12-well plates (Iwaki, Japan) at a concentration of 
1 x 106 cells per well in 4 ml NCM in the presence of 5 ng/ml recombinant murine IL4 
and 5 ng/ml recombinant murine GM-CSF (BD Pharmingen). Half of the medium 
(including all supplements) was replaced every second day. This process removed 
nonadherent granulocytes, whereas clusters of developing DCs remained loosely 
attached. On day 6, non-adherent and loosely attached DCs were harvested (day 6 
HSC-derived DCs). The number of DCs averaged 0.4 x 106 per well stained with anti-
CD11c mAb. For some experiments, DCs were further positively selected according 
to CD11c expression (day 6 CD11c+ HSC-derived DCs) using standard MACS 
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isolation with a MACS LS separation column using CD11c beads. Usually, >70±4.5% 
(mean±SD) of the cells expressed CD11c (clone N418, Miltenyi Biotec, Germany). 
These cells were either activated immediately or re-cultivated in NCM, including 
cytokines, for 24 hours (day 7 CD11c+ HSC-derived DCs).  
 
Isolation of splenic DCs 
Isolation of splenic DCs was done similar to previously described protocols 
(Steinman, Van Voorhis et al. 1986; Vremec, Zorbas et al. 1992; Grohmann, 
Belladonna et al. 1998) with minor modifications. Briefly, 8-10 spleens of C57BL/6 
mice were cut into small fragments and then digested in 10 ml RPMI with 5% FCS 
containing collagenase (1 mg/ml; type IV; Worthington, USA) and DNase I (50 µg/ml, 
Sigma-Aldrich) for 25 minutes at room temperature (RT) with continuous agitation. To 
disrupt DC-T cell complexes, EDTA (1 ml, 0.1 M, pH 7.2) was added and mixing 
continued for 5 minutes. For further disruption and removal of undigested stromal 
fragments, the suspension was rapidly pipetted up and down with 25, 10 and 5 ml 
pipettes, followed by a filtration through a Nylon cell strainer (70 µm, BD Falcon). The 
cells were recovered by centrifugation, and then the pellet was immediately re-
suspended in 10 ml 1.077 g/cm³ NycoPrep (Axis-Shield PoC AS, Oslo, Norway) and 
overlaid with 5 ml RPMI containing 5% FCS. Centrifugation was done at 800 g for 25 
minutes at RT. All remaining procedures were performed at 0-4°C. Low-density cells 
were collected and washed twice in PBS with 5% FCS and 5 mmol/L EDTA. The 
recovered cells were further enriched using magnetic microbeads (CD8+ Dendritic 
Cell Isolation Kit, MACS, Miltenyi Biotec, Germany) to deplete T cells, NK cells, and 
B cells with a cocktail of biotin-conjugated Abs against CD90 (Thy1.2), CD49b (DX5), 
and CD45R (B220) as well as Anti-Biotin MicroBeads. The negative fraction 
containing CD11c+ splenic DCs was eluted on a LD column, washed and 
resuspended with RPMI containing 10% FCS and allowed to adhere in 60-mm dish 
for 2 hrs, followed by an additional incubation to allow DCs to detach at 37°C for 18 
hrs. The recovered cells were routinely 60±3.2% (mean±SD) positive for CD11c+ 
expression. Subsequently, splenic DCs were positively selected according to CD8 
expression using CD8α (Ly-2) MicroBeads and positive selection columns. 
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Activation of HSC­derived and splenic DCs 
For activation, cells were incubated with different reagents for 24 hrs. Day 6 CD11c+ 
HSC-derived DCs were exposed to 500 ng/ml LPS from E. coli O111:B4 
(Calbiochem). Alternatively, 2 µg/ml PolyIC (Sigma-Aldrich, Germany) or 2.5 µg/ml 
R848 (Axxora Platform) was used for the induction of activation. To deliver a 
CD40/CD40L-mediated activation signal, HSC-derived DCs were co-cultured with 
J558L (Lane, Burdet et al. 1995); a kind gift from Dr. H. Strobl) at a ratio of 2 x 106 
HSC-derived DCs/1 x 106 J558L. Alternatively, mAbs directed against CD40 were 
used to trigger CD40 cross-linking as described previously by (Ridge, Di Rosa et al. 
1998; Bianchi, Grohmann et al. 1999) with minor modifications. Briefly, HSC-derived 
DCs were incubated on ice, for 20 minutes with hamster anti-mouse CD40 mAb (5 
µg/ml, clone HM40-3, BD Pharmingen), and then overnight at 37°C with polyclonal 
goat anti-hamster IgG (H+L) (3.3 µg/ml, Pierce Biotechnology) in NCM including 
cytokines. Activation signals, if not stated otherwise, were always applied in 
combination with 10 ng/ml IFN-γ (R&D Systems, UK). The CD8α+ and CD8α- splenic 
DCs were activated with I0 ng/ml IFN-γ alone for 24 hrs. 
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Transfection methods for HSC­derived DCs 
Construction of recombinant plasmids 
For cloning IDO and GFP, primers were designed using available mouse sequences 
from databases (MWG Biotech AG), and RT-PCR was used for amplification from 
cDNA-templates. PCR-fragments of expected sizes were purified from 1% agarose-
gels using the “GFXTM PCR” DNA and Gel BandPurification Kit (Amersham 
Biosciences) and ligated into different expression vectors using T4-ligase 
(Fermentas). Chemically competent E. coli (Top 10F`) were transformed with the 
ligation mixture and plated on LB-IPTG/X-Gal (1.6 mg each, Blue-White Select 
Screening Reagent, Sigma) including 100 µg/ml Ampicillin or Kanamycin to select for 
transformants and to enable blue/white-screening. Plasmid DNA was prepared from 
white colonies, digested with appropriate restriction endonucleases (BioLabs Inc. 
New England) and checked for inserts with correct sizes. All cloned fragments were 
sequenced to confirm insert identity. For expression of the different recombinant 
plasmids, TOP 10F’ E.coli were transformed with the relevant plasmid, a colony was 
picked and cells were grown over night in 6 ml LB-medium including the appropriate 
antibiotic. Plasmids were eluted from the overnight culture with the Fast Plasmid® 
Mini Kit (Eppendorf) or with the EndoFree® Plasmid Maxi Kit (Qiagen) in H2O or TE 
buffer (10 mM Tris-HCl pH 8, 1 mM EDTA pH 8) and either used immediately or 
stored at -20°C. 
 
Primer sequences 
pLenti6/V5-primer 
5`IDO Topo 5`-CAC CAT GGC ACT CAG TAA AAT ATC TCC TAC-3` 
3`IDO Topo 5`-TTG CTA CAC TAA GGC CAA CTC AGA AGA-3` 
5`GFP Topo 5`-CAC CCA CTT TGC CTT TCT CTC CAC AGG-3` 
3`GFP Topo 5`-TGC ATT CTA GTT GTG GTT TGT CCA-3` 
pMax-primer 
5`IDO KpnI 5`-CCG GTA CCA TGG CAC TCA GTA AAA TAT CTC CTA CAG-3` 
3`IDO XhoI 5`-CCC TCG AGC TAA GGC CAA CTC AGA AGA GCT TT-3` 
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Plasmids 
 
 
 
 
 
 
 
 
 
 
 
 
 
For the generation of pLenti6/V5-constructs (Invitrogen), the IDO and GFP 
sequences were amplified from 24 hrs LPS/IFN-γ activated HSC-derived DCs using 
the 5´ and 3´IDO Topo primers and from the pMax-GFP construct (Amaxa AG) using 
the 5´ and 3´GFP Topo primers, respectively. All amplified fragments were cloned 
directly into the pLenti6/V5 vector using the TOPO® Cloning technology for insertion 
of blunt-end PCR products. 
MSC-MigR1-GFP (provided by Dr. W. Ellmeier) contains an internal ribosome entry 
site allowing translation of two open reading frames from one mRNA and a GFP 
gene for testing transfection efficiency. 
pMax-GFP was provided with the Mouse Dendritic Cell Nucleofector® Kit (Amaxa 
AG) and used as a positive control for transfection efficiency with different cell types. 
For the generation of the pMax-IDO construct, the IDO sequence was amplified from 
24 hrs LPS/IFN-γ activated HSC-derived DCs using primers including a KpnI 
restriction site at the 5´end and a XhoI restriction site at the 3´end (5´mIDO KpnI and 
3´mIDO XhoI primers). The fragment was cloned into pCR®2.1 using the TA Cloning® 
method (Invitrogen) which uses a PCR product with adenosine triphosphate at the 
 
 
Figure 31: Schematic representation of the different vectors. 
The lentiviral vectors expressed GFP or IDO under the control of the CMV promoter (A). In 
the retroviral bicistronic vector the GFP was linked to the IRES sequence (B). The vectors 
for lipofectamine transfection and electroporation expressed GFP and IDO under the control 
of the CMV promoter (C). PCMV, promoter of the cytomegalovirus; SV40pA, polyadenylation 
signal; IRES, internal ribosomal entry site of the encephalomyocarditis virus; PCMV IE, 
immediate early promoter of the cytomegalovirus 
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3´ends that can be cloned into a linearized vector with complementary 3´T 
overhangs. After identification of the sequence identity the gene was extracted from 
pCR®2.1 by KpnI and XhoI restriction enzymes (NEW ENGLAND BioLabs) and 
ligated into the expression vector pMax-Cloning (Amaxa) that was linearized with the 
same enzymes. 
 
Lipofectamine transfection 
HSCs or HeLa cells were transfected with pMax-GFP (GFP) using Lipofectamine™ 
2000 according to the manufacturers’ recommendations (Figure 31C). In detail, for 
transfection of HSC-derived DCs 1.6 µg plasmid DNA and 4 µl Lipofectamine™ 2000 
were diluted in 100 µl Opti-MEM® respectively. For HeLa cells 4 µg plasmid DNA and 
10 µl Lipofectamine™ 2000 were diluted in 250 µl Opti-MEM®, respectively. After 5 
minutes incubation at RT both preparations were combined and incubated for 
additional 25 minutes. These lipofectamine transfection solutions were added to 1 x 
106 stem cells in 500 µl NCM supplemented with IL4 and GM-CSF cultured in 12-well 
plates or to 1 x 106 HeLa in 2 ml medium cultured in 6-well plates. Incubation was 
conducted for different time periods. 
 
Lentiviral transfection 
Production of lentiviral particles 
Lentiviral particles were prepared using the ViraPowerTM Lentiviral Expression 
Systems (Invitrogen), according to the manufacturers’ manual. Briefly, the 293FT 
cells were cultured avoiding overgrow and early cell passages (< cell passage 6) 
were taken for production. Replication-defective lentiviral particles pseudotyped with 
the VSV-G envelope were produced by a four plasmid transient transfection of 293FT 
cells with 5.7 µg of pLP1, 5.7 µg of pLP2, 7.5 µg of VSVG and 5.7 µg of pLenti6/V5-
D-Topo containing the gene of interest under the control of the CMV promoter 
(pLenti6/V5-IDO or pLenti6/V5-GFP; Figure 31A). The four plasmids and 68.4 µl 
Lipofectamine™ 2000 were diluted in 2.85 ml Opti-MEM®, respectively. After 5 
minutes incubation at RT both preparations were combined and incubated for 
additional 25 minutes. While DNA-lipid complexes were formed, 293FT cells were 
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trypsinized and 12 x 106 293FT cells were re-plated in 19 ml Opti-MEM with 10% 
FCS using a 150 cm² flask (Iwaki, Japan). After the addition of the DNA-lipid 
complexes the cells were incubated at 37°C for 6 hrs. Then the medium was carefully 
removed and replaced by 30 ml D-MEM fully supplemented, without geneticin. The 
supernatant containing the viral particles was harvested 72 hrs after transfection and 
sterile filtrated through a 45 µm filter to remove contaminating 293FT cells. 
Supernatants were concentrated by ultracentrifugation (28.000 rpm, 14°C, 90 
minutes), resuspended in 300 µl NCM including cytokines (100 times concentrated) 
and either used immediately to transfect HSC-derived DCs or stored frozen at -80°C 
until use. 
Titering the lentiviral stock solution 
In order to obtain the transducing unit of each lentiviral stock, the viral titer was 
determined. On day 0, 2 x 105 HeLa cells were plated in 4 ml RPMI with 2 mM L-
glutamine and 10% FCS in 6 well plates. On day 1, dilutions from 10-2 up to 10-7 of 
the lentiviral stock and 6 µg/ml Polybrene were applied onto the cells in a total 
volume of 1 ml medium. On day 2, the culture supernatant was replaced by 2 ml fully 
supplemented NCM. Transfected Hela cells were selected by replacing NCM 
supplemented with 3 µg/ml Blasticidin (Invitrogen) every second day. Approximately 
14-16 days after transfection no viable cells were left in mock transfected cultures. 
Then the colonies of lentiviral transfected cells were stained by crystal violet and 
counted.  
Transfection of HSC‐derived DCs 
Transfection of day 6 HSC-derived DCs was performed in 48-well plates at a 
multiplicity of infection of one. 1 x 106 DCs were centrifuged and cultured in 100 µl 
NCM containing viral supernatant and supplemented with 5 ng/ml IL4, 5 ng/ml GM-
CSF and 8 µg/ml Polybrene for 18 hrs. Then the transfection medium was replaced 
by NCM including cytokines and incubation continued for different periods of time.  
 
Retroviral transfection of HSCs and differentiation into DCs 
Retroviral transfection was done according to an established protocol (Specht, Wang 
et al. 1997) with minor modifications. Briefly, 24 hrs previous to transfection, 1 x 106 
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Phoenix-Eco retrovirus packaging cells (kind gift from Dr. W. Ellmeier) were cultured 
in 6 well plates in 2 ml medium. The cell line transiently expresses the retroviral gag, 
pol and env proteins for ecotropic retroviruses. Sub-confluent Phoenix cells were 
transfected with MSCV-MigR1-GFP retroviral vector (Figure 31B), using 
Lipofectamine™ 2000 reagent, according to manufacturers’ recommendations. 
Briefly, 4 µg retroviral vector and 10 µl Lipofectamine™ 2000 were diluted in 250 µl 
Opti-MEM®, respectively. After 5 minutes incubation at RT both preparations were 
combined and incubated for additional 25 minutes. This lipofectamine transfection 
solution was added to Phoenix cells in 2 ml medium for 24 hrs before irradiation (30 
Gy). Then, 2 x 106 cells were re-cultured in 2 ml medium in 6 well plates for additional 
24 hrs. Freshly prepared HSCs (7.5 x 105 cells/ml) were added to the irradiated 
Phoenix cells (1.5 x 106 cells/well) and cultured with 2 ml NCM in the presence of 5 
ng/ml IL4, 5 ng/ml GM-CSF and 8 µg/ml Polybrene (Sigma). On day 2, co-cultures 
were terminated upon removal of target cells by gentle swirling and pipetting to avoid 
detachment of the viral packaging cell line. DCs were re-plated at a concentration of 
7.5 x 105 cells/ml in 1 ml NCM including cytokines in 24 well plates. On day 3, one ml 
of NCM including cytokines was added to each well. On day 6, HSC-derived DCs 
were harvested by gentle pipetting and analyzed. 
 
Electroporation 
1 x 106 of day 7 CD11c+ HSC-derived DCs or 1 x 106 cells of each cell line were 
resuspended in 100 µl Mouse DC Nucleofector® Solution (Mouse Dendritic Cell 
Nucleofector® Kit, Amaxa AG) containing either 2 µg pMax-GFP (GFP) or a 
combination of 1 µg pMax-GFP and 1 µg pMax-IDO vector (IDO/GFP) (Figure 31C). 
DCs were transfected with the Y-001 Nucleofector® program on the Nucleofector™ 
and then resuspended in 800 µl pre-warmed NCM including 5 ng/ml IL4 and 5 ng/ml 
GM-CSF and transferred into 24 well plates. The different cell lines were transfected 
with the appropriate program and then resuspended in the respective medium and 
transferred into 6 well plates. At different time points after treatment cells and 
supernatant were analyzed. 
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Analyzing methods 
Flow cytometry 
Cells were centrifuged and surface staining was performed by blocking Fcγ receptors 
with anti-CD16/CD32 (mouse, clone 2.4G2, BD Pharmingen) mAb followed by 
staining with fluorochrome- or biotin- conjugated mAbs (CD11b-PE (clone M1/70), 
CD11c-APC (clone HL3), CD80/B7-1-Biotin (clone 16-10 A1), CD86/B7-2-Biotin 
(clone GL1), MHC class II/I-A/I-E-FITC (clone 2G9), CD40-FITC (clone 3/23), 
CD8α/Ly-2-PerCP (clone 53-6.7); all obtained from BD Pharmingen, San Diego, CA) 
using 1 x 105 cells per staining. CD4 or CD8 T cells subsets were stained with a 
cocktail including CD3ε-FITC (clone 145-2C11), CD4/L3T4-PerCP (clone RM4-5) or 
CD8α/Ly-2-PerCP (clone 53-6.7). Cells were stained with labeled mAb for 30 minutes 
at 4°C. After washing with PBS, Streptavidin PerCP was added to cells labeled with 
Biotin conjugated mAbs for 15 minutes at 4°C. After an additional washing step with 
PBS, the supernatant was discarded and the cells were analyzed on a FACScalibur 
flow cytometer (Becton Dickinson, San Jose, CA, USA). The viability of the cells was 
measured by addition of 7-AAD (BD, Pharmingen) shortly before measurement. For 
exact cell numbers the Trucount system (BD Bioscience) was used. Appropriate 
isotype control Abs were included in the analyses. Data analyses were performed 
with CellQuest software (Becton Dickinson). 
 
IL­12 ELISA  
Levels of IL-12 p40/p35 (IL-12p70) heterodimer were determined in the supernatants 
of DC cultures by ELISA (OptEIA, BD Biosciences). ELISA plates were coated with 
anti-mouse IL-12 (p70) mAb (BD Biosciences) in PBS overnight at 4°C. On the 
following day, the plates were washed with PBS and incubated with 250 µl blocking 
solution (2% bovine serum albumin (BSA) in PBS) at RT for 3 hrs. After washing the 
plate, standards and samples were added at the appropriate dilution and incubated 
at RT overnight. After an additional washing step, the biotinylated anti-mouse IL-12 
(p70) mAb (BD Biosciences) was added in PBS with 1% BSA and incubated at RT 
for 4 hrs. After the next washing step, incubation with streptavidin-alkaline 
phosphatase in PBS with 1% BSA (Chemicon, Temecula, CA, USA) at RT followed. 
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After 1 hr ,the solution was replaced by 100 µl phosphatase substrate (Sigma-
Aldrich) in diethanolamine buffer (1 M diethanolamine, 0.5 mM MgCl2, 120 mM HCl, 
pH 9.8), the plates were incubated in the dark at RT for 10 minutes and then 
measured with an ELISA plate reader (Anthos, Salzburg, Austria) at 405 nm using 
690 nm as reference wavelength. The cytokine content was calculated using 
recombinant standards. 
 
Protein expression studies by western blot analysis 
For the preparation of protein extracts from different cell cultures, cells were 
harvested, washed twice with 1x PBS and lysed by addition of 50 µl per 1 x 106 cells 
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl (pH 7.4), 1% NP-40, 
0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA) supplemented with 
protease inhibitors (Complete Protease Inhibitor Cocktail Tablets, Roche) for 10 
minutes at 4°C. After centrifugation, 4x NuPAGE LDS Sample Buffer was added to 
the supernatant containing the whole cell lysate and proteins were denaturated for 5 
minutes at 95°C. After cooling on ice, the samples were either used immediately for 
analyses or stored at -80°C for extended periods. Marker (BenchMark™ Pre-Stained 
Protein Ladder (6-180 kDa); Invitrogen) and protein samples were fractionated on a 
NuPAGE 4-12% Bis-Tris gel (Xcell SureLock Mini-Cell; Invitrogen, Carlsbad, CA) for 
90 minutes with 170 Volt. To visualize proteins separated by gel electrophoresis, the 
gels could be stained with Coomassie staining solution for 1 hr up to overnight, and 
destained with destain solution (5% methanol, 7% acetic acid, 88% A.d.) until 
sufficient contrast was reached to detect the bands of interest. Proteins on gels used 
for immunoblot analysis were transferred to a polyvinylidene difluoride membrane 
(Immobilon Transfer Membrane, 0.45 µm, Millipore) by electroblotting for 60 minutes 
with 30 Volt. In order to control the efficiency of blotting, and for quantifying the 
amount of protein in a given lane, membranes were reversibly stained with 1x 
PonceauS Red (Sigma). After destaining with A.d., membranes were used for 
immunodetection. The membrane was immersed in 1x blocking reagent (Roche 
Diagnostics GmbH, Germany) at RT for 1 hr. Incubation with the appropriate dilution 
of primary Abs (diluted in 0.5% blocking reagent) overnight at 4°C was followed by 
washing three times for 5 minutes with 0.05% PBS-tween. The horseradish 
peroxidase (HRP) conjugated secondary Abs were applied (diluted in 0.5% blocking 
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reagent) at RT for 1 hr and membranes were washed afterwards as described 
previously. Immobilized proteins were visualized by chemiluminescence detection 
(SuperSignal West Pico Chemiluminescent Substrate; Pierce), according to the 
manufacturers recommendations. Detection was performed by exposing the Saran 
Wrap wrapped membrane briefly (5 seconds to 15 minutes) to an X-ray film. 
Primary Abs 
- rabbit anti-mouse IDO polyclonal Ab (1:1000, kindly provided by O. Takikawa) 
- mouse anti-mouse GAPDH mAb (1:1.000.000, IgG1, Ambion) 
Secondary Abs 
- goat anti-mouse IgG (H+L), HRP conjugated (1:10.000, Pierce) 
- goat anti-rabbit IgG (H+L), HRP conjugated (1:10.000, Pierce) 
 
Gene expression studies by RT­PCR 
Total mRNA was isolated from cell populations with the RNeasy Mini kit (Qiagen) and 
stored at -80°C or immediately used for cDNA preparation. First-strand cDNA 
synthesis was started by heating 2 µg of total mRNA with 2 µg random hexamer 
pd(N)6 (GE Healthcare) in a total volume of 27.4 µl to 70°C for 5 minutes, followed by 
a short incubation on ice. After the addition of 40 U Recombinant Rnasin® 
Ribonuclease Inhibitor, 200 U M-MLV Reverse Transcriptase and 1x M-MLV Reverse 
Transcriptase Reaction Buffer (Promega) in a total volume of 40 µl, the sample was 
incubated at 37°C for 1 hr. cDNA preparations were stored at -80°C or immediately 
used for experiments. Primers (MWG Biotech AG) used for amplification of the 
murine IDO or of the murine GAPDH as internal control and PCR product sizes are 
listed in Table 2. Cycling variables on the Gene Amp® PCR System 9700 (Applied 
Biosystems) were as followed: 10 minutes at 95°C and 35 cycles of 15 seconds at 
95°C, 30 seconds at 58°C and 1 minute at 72°C, followed by 7 minutes at 72°C and 
then 4°C. Usually 10 µl of the preparation was loaded on a 1% agarose gel. 
Table 2: Oligonucleotides and PCR product sizes for the determination of IDO and control gene 
expression. 
Gene Sense primer Antisense primer Amplicon size (bp) 
IDO CGA CAT AGC TAC CAG TCT GGA GAA AG GCG AGG TGG AAC TTT CTC ACA GAG 441 
GAPDH ACC ACA GTC CAT GCC ATC AC TCC ACC ACC CTG TTG CTG TA 452 
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Quantification of Kyn, TRP and NO 
The IDO enzymatic activity was determined by measuring the levels of TRP and Kyn 
in the cell culture supernatants in cooperation with D. Fuchs (Institute of Medical 
Chemistry and Biochemistry, University of Innsbruck, Austria) as previously 
described (Hainz, Obexer et al. 2005). Briefly, TRP was detected by its natural 
fluorescence at 286 nm excitation and 366 nm emission wavelengths. 3-nitro-L-
tyrosine, used as an internal standard, and Kyn were determined by ultraviolet (UV) 
absorption at 360 nm. An albumin-based external standard mix was prepared that 
included 50 µM TRP (Serva, Heidelberg, Germany), 10 µM Kyn (Sigma) and a frozen 
serum-pool. Upon the addition of 25 µl 2 M trichloroacetic acid (Merck, Darmstadt, 
Germany), reaction vials were immediately vortexed and centrifuged at 12000 g for 6 
minutes at RT to precipitate protein. The concentration of the components was 
calculated according to peak heights and was compared to 3-nitro-L-tyrosine as a 
reference standard. 
Measuring levels of nitrate and nitrite in the cell culture supernatants are used for 
indirect evaluation of NO synthesis by iNOS activity. The iNOS activity was 
determined in cooperation with D. Fuchs (Institute of Medical Chemistry and 
Biochemistry, University of Innsbruck, Austria) as previously described (Maloney, St 
Claire Morgan et al. 2000). Briefly, cell supernatant concentrations of total nitrite and 
nitrate were measured by the Griess reaction: 75 µl A.d. and 125 µl Griess reagent 
were added to 50 µl of samples and the mixture is incubated for 10 min at RT. A 96-
well-reader/photometer was used for determination of the absorption at 560nm. 
 
Proliferation assay 
Day 7 CD11c+ HSC-derived DCs were either transfected with pMax-GFP (GFP), co-
transfected with pMax-IDO and pMax-GFP (IDO/GFP) or left un-transfected. 
Subsequently, cells were stimulated with 500 ng/ml LPS and 10 ng/ml IFN-γ and 
simultaneously either loaded with 10 ng/ml SIINFEKL-peptide (OVA257-264/H-2Kb) or 
10 µg/ml OVA-peptide (OVA323-339/I-Ab, genXpress Service). During the 3 hrs 
incubation period of DCs, CD4 or CD8 T cells were enriched from OT2 and OT1 
transgenic mice, respectively. T cells of these mice express a transgenic TCR 
specific for OVA-peptide323–339 in the context of MHC class II H-2Kb (OT2 CD4 T 
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cells) or OVA-peptide 257-264 (SIINFEKL), presented by MHC class I H-2Kb (OT1 CD8 
T cells). Spleens from these TCR transgenic mice were washed in PBS and then 
filtrated through a nylon cell strainer (70 µm, BD Falcon). Cells were collected, 
centrifuged and resuspended in 1 ml of a hypotonic buffer (0.15 M NH4Cl, 10 mM 
KHCO3, 0.1 mM, Na2EDTA, pH 7.2-7.4) to lyse red blood cells. After 5 minutes 
incubation, 20 ml NCM were applied and cells were centrifuged twice to remove the 
hypotonic buffer. The OT2/CD4 and OT1/CD8 T cells were further enriched using 
magnetic microbeads (CD4+ T Cell Isolation Kit for OT2/CD4+ T cells and CD8α+ T 
Cell Isolation Kit for OT1/CD8+ T cells, MACS, Miltenyi Biotec, Germany) to deplete 
NK, monocytes, B cells and erythrocytes with a cocktail of biotin-conjugated Abs 
against CD11b (Mac-1), CD45R (B220), DX5 and Ter-119. Further, CD8 T cells were 
depleted from CD4 T cell enrichment with a biotin-conjugated Ab against CD8α+ and 
CD4α T cells from CD8 T cells enrichment with a biotin-conjugated Ab against CD4 
(L3T4). Enriched OT-2/OT-1 T cells were labeled with 10 nM CFSE (Invitrogen, 
Eugene, Oregon, USA) for 5 minutes at 37°C in PBS, washed twice and cultured at a 
concentration of 1 x 105 T cells per well in a 96 well plate (round bottom) in 100 µl 
NCM. After incubation the differently treated DCs were harvested and the exact cell 
number of viable DCs was assessed by staining dead cells with 7-AAD using the 
Trucount system (BD Pharmingen, according to the manufacturers’ 
recommendations). DCs were co-cultured with 105 T cells in graded DC-T cell ratios 
as indicated. Resting T cells served as negative control and CD3 cross-linked T cells 
(1 µg/ml αCD3 mAb) served as positive control. DCs cultured alone were analyzed in 
addition 24 hrs later. Proliferation was determined after 3 days when T cells and 
supernatants were used for different analyses. Proliferating T cells were defined by 
their loss of green fluorescence due to CFSE dilution compared to maximum green 
fluorescence in un-proliferated T cells.  
 
Statistical analysis 
Data are presented as mean values±standard deviations of at least three separate 
experiments. The two-tailed Student`s t-test was used to determine statistical 
significance between two differentially treated cultures. Differences were considered 
significant if p≤0.05. 
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